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U N I V E R S I T Y  O F  E D I N B U R G H
ABSTRACT OF THESIS 7.»,
The work reported in this thesis is an inherent part of research 
carried out in Edinburgh to assess the performance and durability of heart 
valve prostheses. Frcm 1975 to 1979 540 patients undergoing heart valve 
replacement in Edinburgh Royal Infirmary were entered into a randomised 
trial and received either a mechanical (Bjork-Shiley), or porcine 
heterograft (Hancock or Carpentier-Edwards) prosthesis. Starting in 1977 
in the United States the Veterans Administration carried out a similar 
randomised trial on 575 patients. After a mean period of 5 years no 
significant advantage to any of the three prostheses was observed, 
although there were some differences in the results reported in the 
Edinburgh and the US trials and possible explanations for these are 
proposed.
This thesis extends the analysis of the trial to a mean period of 
10.5 years with respect to survival, and the incidence of reoperation, 
complications of anticoagulation, systemic embolism and bacterial 
endocarditis. It also presents a Doppler ultrasound comparison of the 
haemodynamic performance of the different valves in a subset of 102 
patients.
After this extended follow-up period we have again observed no 
difference in survival between those receiving a mechanical or porcine 
prosthesis. Reoperation for valve failure was necessary significantly 
more often in patients with porcine prostheses (53 patients) than in those 
with the Bjork-Shiley prosthesis (17 patients). This difference was 
almost entirely due to cusp failure of porcine prostheses occurring more 
than 5 years after implantation. An actuarial analysis of valve survival 
using reoperation or cardiac death as end-points showed significantly 
better valve survival for patients receiving the Bjork-Shiley prosthesis 
when all patients and the subgroup undergoing mitral valve replacement 
were considered, but not in the subgroup receiving an aortic valve 
replacement.
All patients with Bjork-Shiley prostheses received longterm 
anticoagulation therapy, and bleeding complications were more frequent in 
this group. Death, reoperation, bleeding and complications of 
anticoagulation, .systemic embolism and bacterial endocarditis were taken 
as end points for an actuarial analysis of "event-free survival". There 
was a non-significant trend in favour of the Bjork-Shiley prosthesis when 
all patients and the subgroup undergoing mitral valve replacement were 
considered, but no discemable trend after aortic valve replacement.
Doppler ultrasound techniques have been used to compare the 
haemodynamic performance of the Bjork-Shiley and porcine prostheses an 
average of 10 years after implantation in 102 patients enrolled in the 
Edinburgh trial. No significant difference in peak instantaneous or mean 
pressure gradient across the prosthesis was observed in patients who had 
undergone aortic or mitral valve replacement. There was however a 
significantly lower pressure half-time in patients with Bjork-Shiley 
compared with those with porcine mitral valve prostheses but this fell 
after exercise in those with porcine mitral prostheses, suggesting that 
this difference, observed at rest does not indicate better haemodynamic 
performance of the Bjork-Shiley prosthesis.
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In 1923 Cutler and Levine reported successful 
treatment by closed mitral valvotomy of a 12 year old girl 
dying of severe mitral stenosis. The opening paragraphs of 
their report read:
"During the recent bicentenial of the former and 
present members of the nursing and professional staff of 
the Peter Bent Brigham. Hospital, we presented a case of 
mitral stenosis upon which we had operated four days 
previously in an attempt to alleviate the condition by 
diminishing the degree of stenosis of the valve. It so 
happened that Professor Wenkebach of Vienna was visiting 
our clinic just at this time. The great enthusiasm and 
approval of the method of attack that he manifested, and 
the considerable discussion and general interest that the 
presentation of the case aroused, made it appear advisable 
to us to detail as exact a preliminary report as is 
possible at the present time."
Over the ensuing decades closed mitral valvotomy 
became established as a safe and highly effective treatment 
for patients with rheumatic mitral stenosis, and proved to 
be a successful treatment relieving symptoms usually for 
many years after operation. This procedure only reguires 
conventional operating facilities and has brought the 
benefits of cardiac surgery to thousands of people not only 
in Western industrialised nations, but also throughout the 
Third World.
Patients with heavily diseased, fibrotic or calcified
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mitral valves, those in whom fibrosis and calcification has 
progressed following initial successful valvotomy, and 
those with regurgitation of the diseased valve cannot 
benefit from valvotomy. In 1960, using techniques of 
cardiopulmonary bypass pioneered by Cooley (1958), Harken 
in Boston, Massachusetts and Starr in Portland, Oregon 
first used ball and cage mechanical prosthetic valves to 
replace diseased aortic and mitral valves in patients with 
severe heart failure (Harken et al 1960, Starr et al 
1961). Only one of Harken's five patients survived to 
leave hospital. Starr's first patient died within 24 hours 
but six of the following seven survived. This operative 
treatment of patients with severe valvular heart disease 
radically changed the management of these patients and 
between 1963 and 1964 McGoon et al (1964) were able to 
report an unmatched surgical accomplishment at the Mayo 
clinic; the first one hundred patients in whom he replaced 
aortic valves survived. He almost exclusively used the 
prosthesis developed by Starr and Edwards, a device which 
is still used in modified form today and continues to be 
preferred by some surgeons. Operative mortality was also 
reduced dramatically following improvement in techniques of 
myocardial preservation, a major problem in valve 
replacement surgery being myocardial failure following 
cardiopulmonary bypass. This improvement was largely due 
to the introduction of cold potassium cardioplegia in 
addition to coronary perfusion (Richardson et al 1979).
Systemic embolisation was the most frequent 
complication of the Starr-Edwards and other mechanical
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valve replacements, and early clinical experience with 
patients undergoing valve replacement with mechanical 
prostheses indicated that long term systemic 
anticoagulation with warfarin was essential if this risk 
was to be reduced (Barnhorst et al 1975). The persistent 
problem of thromboembolism and the need for anticoagulation 
with its attendant hazards led to the search for a suitable 
biological valve replacement; this would have a lower risk 
of thromboembolism, which might avoid the need for long 
term anticoagulant treatment. Ross (1962) and Barratt-
Boyes (1964) used antibiotic sterilised homograft valves 
and achieved good medium term results (Barratt-Boyes 1977). 
Valves constructed from the patient's own fascia lata, at 
the time of valve replacement, proved to have only limited 
durability. In 1965 a glutaraldehyde-treated bioprosthesis 
from a calf was first used for valve replacement in a human 
(Binet et al 1965). Subseguently, heterograft
bioprosthetic valves were produced commercially and were 
used widely. In some centres they became the type of
prosthesis most freguently used for heart valve
replacement, despite the absence of information about their
long term durability. Carpentier, having taken part in the 
very early development of heterograft bioprosthesis, 
continued his work which led to the commercial development 
of the Carpentier-Edwards prosthesis. In 197 6 when there 
was unbounded enthusiasm for the use of these 
bioprostheses, Carpentier himself stated: "We can predict
that at the end of ten years the valve failure rate will be 
20%" (Carpentier A, in discussion of Cohn L H et al 1976).
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The first indications that bioprosthetic valves might 
prove to have limited durability were in children and young 
adults. In children prosthetic failure due to
calcification of leaflet tissue frequently occurred within 
a few years of implantation necessitating reoperation 
(Curcio C A et al 1981; Magilligan D J et al 1985). 
Calcific stenosis of a bioprosthesis inserted in the mitral 
position has been reported in a young adult within a month 
of implantation (Forfar et al 1978).
Difficulties in the evaluation of the comparative 
merits of different types of prosthetic valve, whether 
mechanical or biological, are compounded by the effects of 
a variety of clinical features of patients undergoing valve 
replacement (Mitchell R S et al 1986). Age, sex, the 
presence of associated coronary artery disease, all 
influence outcome after valve replacement. Atrial 
fibrillation and enlargement of the left atrium are 
associated with systemic embolisation. Research carried 
out in the last 10-15 years has highlighted the influence 
of ventricular volume and function on survival and 
symptomatic status after valve replacement (Hammermeister 
et al 1978). The impact of all these "patient-related 
variables" complicates the evaluation of the effect of the 
type of prosthesis on patient survival, systemic 
embolisation and symptomatic status following valve 
replacement (Rahimtoola 1983).
The prospective, randomised controlled trial has long 
been established in the evaluation of different types of 
medical treatment, but has only infrequently been applied
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in the evaluation of surgical procedures. Bioprosthetic 
valves had the advantage of an apparent reduced risk of 
thromboembolism, and by 1974 these valves had gained 
widespread acceptance and indeed were considered by many 
surgeons to be the optimal type of valve prosthesis for 
most patients. The durability of these devices had not 
however been established as it has been for mechanical 
prostheses and at that time no prospective randomised 
trial had been planned to compare the results of valve 
replacement using these prostheses with the already 
established mechanical prostheses. The time was right that 
the comparative merits of bioprosthetic and mechanical 
valves should be evaluated in the context of a prospective 
randomised controlled trial.
In 1975 Dr Hugh C Miller at Edinburgh Royal Infirmary, 
in collaboration with all the other consultant 
cardiologists in Edinburgh and with three cardiac surgeons, 
started a prospective randomised trial to compare early and 
long term results with the Bjork-Shiley tilting disc 
mechanical prosthesis, and with the Hancock porcine 
heterograft bioprosthesis. In 1977, in the United States, 
the Veterans Administration (VA) commenced a similar 
prospective randomised trial recruiting patients from 
thirteen different VA medical centres throughout the 
country in which the Bjork Shiley mechanical prosthesis was 
to be compared with the Hancock porcine bioprosthetic 
valve. Results of the Edinburgh trial, up to a median of
5.6 years of follow-up, were published in 1986 (Bloomfield 
et al 1986), and results of the VA cooperative study, also
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up to a mean of 5 years of follow-up, were published in 
1987 (Hammermeister et al 1987). These results are 
presented and compared in Chapter 2.
Patients enrolled in the Edinburgh trial have now been 
followed for a mean of 10.5 years (range 7.5 to 12.5 years) 
and the results are presented in Chapters 2 and 3. The 
aims of the study were:
(1) To compare survival in the groups of patients 
receiving each type of prosthesis.
(2) To compare the occurrence of complications possibly 
related to the type of prosthesis i.e. the need for 
reoperation due to valve failure, systemic 
embolisation, bacterial endocarditis, and bleeding 
related to the use of anticoagulant drugs.
(3) To try to define which patients might benefit from 
the use of one type of prosthesis in preference to 
the other.
Until recently, there was no way in which the 
haemodynamic performance of the different prostheses could 
be compared after implantation without the use of invasive 
methods, that is cardiac catheterisation. This procedure 
is potentially dangerous in patients on anticoagulant 
treatment, and it was not carried out in patients enrolled 
in the Edinburgh trial. Cardiac catheterisation was 
carried out in about half of the patients enrolled in the 
VA Cooperative study shortly after surgery. Khuri et al 
reported in 1988 that, at six months after implantation, 
the Bjork Shiley valve appeared to possess marginally 
superior haemodynamic characteristics when used in the
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aortic position, but there was no difference in the mitral 
position. No evidence was quoted from the VA Cooperative 
study on whether or not this superior haemodynamic 
performance equated with improved symptomatic results. 
Other workers have investigated the haemodynamic 
performance of implanted mechanical and bioprosthetic 
valves "in vivo", but this has almost invariably been with 
small numbers of patients and usually within one year of 
implantation (Bjork et al 1973, Lurie et al 1977, Cotter 
and Miller 1979, Thormann et al 1981, Horskotte et al 1983, 
Gray et al 1984) .
With the accelerated degeneration of bioprosthetic 
valves which had been observed in children and young 
adults, it seemed likely that lesser degrees of 
degeneration and consequent impairment of haemodynamic 
performance might occur in adult patients implanted with 
such prostheses. Lipson et al (1982) studied a group of 54 
patients undergoing valve replacement with the Hancock 
bioprosthetic porcine valve. All underwent catheterisation 
seven months after operation, and a further eighteen 
volunteered to have a second catheterisation seven years 
after operation. There was a significant increase in the 
mean pressure gradient across the mitral prosthesis over 
this period from 5.9 ± 0.7 mmHg to 8.6 ± 0.7 mmHg. The 
calculated valve area fell from 2.2 ± 0.2 cm2 to 1.7 ± 0.2 
cm^. Furthermore, in seven of the patients the valve area 
fell by more than 1 cm2 over this period of time.
In patients implanted with mechanical prostheses in­
growth of a panus of fibrin-like material has been observed
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around the sewing ring on occasion causing dysfunction of 
the prosthesis (Yoganathan et al 1978). It appeared 
therefore that both types of prosthesis could be prone to 
deteriorate in perforinance over time (Roberts 1976). 
Furthermore, both mechanical and bioprosthetic valves are 
known to fail and to require replacement, the former most 
frequently because of thrombosis (Bjork and Henze 1979; 
Karp et al 1981) and the latter due to failure of the valve 
cusps. Bioprosthetic valve failure has been reported to be 
mostly gradual, but occasionally catastrophic. Thrombosis 
of the Bjork Shiley prosthesis usually leads to rapid 
clinical deterioration and often death unless thrombosis is 
reversed with thrombolytic treatment (Luluaga et al 1971), 
or the valve replaced.
Doppler ultrasound techniques enable measurement of 
the velocity of blood within blood vessels and the cardiac 
chambers. Light and Cross (1972) showed that the velocity 
integral recorded from blood flow in the aorta related to 
stroke volume. The development of Fast Fourier Transform 
spectral analysis of Doppler recordings of blood flow, 
facilitated the identification of the high velocities 
associated with valvular heart disease. Hatle and Angelsen 
used Doppler to measure these high jet velocities and 
predict valvular pressure gradients. The authors 
summarised their findings in the first clinical book 
exclusively written about Doppler methods in cardiology 
(Hatle and Angelsen 1982). Virtually all work published 
subsequently on the derivation of pressure gradients have 
been based on the concepts developed by them. These
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concepts can also be applied to the measurement of pressure 
gradients across prosthetic valves and to the detection of 
associated regurgitant flow. This technique, therefore, 
for the first time enabled the haemodynamic performance of 
prosthetic valves to be assessed "in vivo" without using 
cardiac catheterisation.
A Doppler ultrasound machine was obtained in the 
Royal Infirmary in 1985 with which the function of 
prosthetic valves could be assessed. The aim of the work 
described in the latter part of this thesis was to 
determine if there was any difference in haemodynamic 
performance as determined by Doppler echocardiography 
between the Bjork Shiley and porcine bioprostheses 8 to 12 
years after implantation.
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REVIEW OF THE EDINBURGH AND VETERANS ADMINISTRATION 
RANDOMIZED TRIALS COMPARING PORCINE AND MECHANICAL
PROSTHESES. RESULTS AT 5 YEARS
The prognosis of patients with valvular heart disease 
is influenced by many factors. The age, sex, race, smoking 
habits, social class etc may be important influencing 
longevity in patients with valvular heart disease as in any 
other group of subjects. In addition the presence of
associated coronary artery disease is known to influence 
survival following valve replacement (Czer et al 1984) and 
other factors such as ventricular function, the degree of 
pulmonary hypertension, the presence of atrial 
fibrillation, and other features would be expected to 
influence, not only survival, but the risk of morbid events 
such as systemic embolisation (Hammermeister et al 1978). 
It was clear, therefore, that a study to compare results 
after valve replacement with a porcine or mechanical
prosthesis in a randomised trial would require a large 
enough group of patients so that these features would be 
equally represented in two treatment groups.
The Edinburgh heart valve replacement started in 
December 1975 and patients were allocated to treatment with 
a Hancock porcine valve prosthesis or a Bjork Shiley 
mechanical tilting disc prosthesis. In September 1977 The 
Veterans Administration (VA) Cooperative Study on Valvular 
Heart Disease was started and it too was to compare the 
Hancock porcine and Bjork-Shiley mechanical prosthetic 
valves; it was designed in a similar way to the Edinburgh
CHAPTER 2
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trial. Accession to the Edinburgh study was completed in 
August 1979, and to the VA study in September 1982, and I 
am fortunate to have a unigue personal view of both 
studies. From July 1980 through June 1983 I worked in the 
Veterans Administration Medical Centre in West Roxbury 
Massachusetts, one of the largest centres participating in 
the VA study, and dealt with some of the patient population 
participating in the study. In 1983 upon returning to 
Edinburgh I was asked by Dr Hugh Miller to help with data 
collection and analysis of results of the Edinburgh trial, 
and I have also seen many of the patients participating in 
this study. The patient population, eligibility criteria 
and designs of the two trials are presented in this 
chapter; there are important differences in the populations 
studied in each trial and these are discussed later in 
this chapter and in chapters 3 and 4. The results after a 
mean of 5 years of follow-up are summarised from previously 
published work for both studies (Bloomfield et al 1986, 
Hammermeister et al 1987). As the main thrust of this 
thesis is an assessment of the long term results of valve 
replacement, only this part of the data is presented, and 
operative mortality is not discussed. The results of the 
Edinburgh study after a mean follow-up period of 10.5 years 
are presented in Chapters 3 and 4.
THE EDINBURGH STUDY 
Patients and Methods
All patients reguiring valve replacement who had been 
examined in the two hospitals involved in the study were 
seen by six consultant cardiologists and were considered
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for entry to the study. Patients were excluded if long 
term anticoagulation was contraindicated, and those in the 
study who required another valve replacement were not 
reentered into the study. Three of the five cardiac 
surgeons participated in the trial.
A comprehensive clinical profile with 34 preoperative 
clinical variables and data from cardiac catheterisation 
was recorded for each patient (84.5% of the patients had 
cardiac catheterisation) Table 2.1. Coronary angiography 
was performed only when coronary artery disease was 
clinically suspected and disease was considered significant 
if there was a 70% or greater obstruction in a major 
coronary vessel.
At the time of the operation, if there were no 
technical reasons for preferring one prosthesis over the 
other, an envelope that indicated the prosthesis to be 
allocated to the patient was opened. Randomization of the 
envelopes was in groups of ten to ensure even distribution 
of prostheses should the trial need to be terminated 
prematurely or modified - as did in fact occur. The 
surgeons used a standardized technique, and cold 
cardioplegia was used routinely. Details of the size of 
the prosthesis, the total cross-clamp time, the total 
bypass time, the amount of blood transfused, and the need 
for postoperative inotropic support were all recorded.
Patients with Bjork-Shiley valves received warfarin 
indefinitely following surgery. All patients with porcine 
valves were given warfarin for two months post-operatively, 
but thereafter anticoagulation was at the discretion of the
16




Aetiology of valve disease 
NYHA clinical grade
Drug therapy, including anticoagulants 
Previous thrombo-ernbolism 
Previous cardiac surgery 
12 lead ECJG 
Chest x-ray
♦Cardiac catheterisation data; right and left sided 
pressures, valve gradients, arterial and mixed venous 
oxygen saturation and cardiac index 
Coronary angiography; vessels involved and severity of 
lesion
*84 patients (15.5%) did not undergo cardiac 
catheterisation
TABLE 2.1
referring physician and practice varied widely. Some 
physicians changed their patients' treatment during the 
course of the study and resumed anticoagulation that had 
previously been stopped. Any patient not on anticoagulants 
who developed an embolus was automatically restarted on 
anticoagulants.
Methods
The majority of patients were followed up by one of 
the principal investigators or by their local physician. 
Thirty-six patients were interviewed by questionnaire. 
Details of any possible embolic event were specifically 
sought, and any residual signs were documented. Valve 
failure was defined to include malfunction of the 
prosthesis, endocarditis, or multiple embolic events that 
resulted in the death of the patient or replacement of the 
prosthesis. After successful reoperation, patients were 
withdrawn from the study.
Deaths related to the valve replacement operation were 
defined as those that occurred before hospital discharge. 
Other deaths were classified as cardiac, noncardiac, or 
possibly cardiac, on the basis of the clinical and autopsy 
evidence available. In addition, deaths were classified as 
prosthesis-related if this was appropriate. Deaths due to 
embolism or a complication of anticoagulation were 
classified as cardiac, and deaths due to embolism or 
occurring at reoperation were classified as prosthesis- 
related.
Statistical analysis employed the t-test for the 
continuous variables of age and follow-up length, and the
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Fisher exact test and the Pearson Chi-square test for 
categorical analysis. The rates of survival, valve 
failure, thromboembolism, and anticoagulant-related 
haemorrhage were expressed in the form of standard life 
tables. The generalized Wilcoxon and Mantel-Haenzel tests 
were used to test for differences in survival. Continuous 
data are presented as mean + SD, and actuarial probability 
estimates as mean + 2 SEM.
Of the 811 patients who underwent valve replacement in 
Edinburgh Royal Infirmary during the study period, 612 were 
referred for valve replacement to the three participating 
surgeons. Seventy-two of these patients were excluded from 
the study because of inability to take anticoagulants or 
because there were technical reasons to prefer one type of 
prosthesis, and the 540 remaining patients were randomized. 
Because of their low number, the eight patients who 
underwent tricuspid valve replacement were excluded from 
further analysis. Of the remaining patients, 262 had 
mitral valve replacement, 210 had aortic valve replacement, 
and 60 had combined aortic and mitral valve replacement.
From December 1975 to January 1977, patients 
randomized to treatment with a porcine xenograft prosthesis 
received a Hancock prosthesis (107 patients), but 
thereafter because of cost, the Carpentier-Edwards 
prosthesis was used (159 patients). Patients randomized to 
receive a mechanical prosthesis received the Bjork-Shiley 
valve throughout (266 patients). It seemed possible that 
time of operation might exert a separate bias, but results 
of valve replacement with Bjork-Shiley prostheses were
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similar in the two time periods, consequently results were 
analysed as a simple comparison of the three prostheses.
The randomization procedure worked well, and there was 
no statistically significant difference in the distribution 
of any of 34 preoperative variables among groups identified 
by prosthesis used for patients having aortic, mitral, or 
aortic plus mitral valve replacement. Patients not
catheterised preoperatively were randomly distributed in 




Of the 487 patients leaving hospital, only six were 
lost to follow-up. The median duration of follow-up was
5.6 years (range 2.8 - 8.3 years). There were 113 late 
deaths during this follow-up period. The causes of death 
(cardiac, possibly cardiac, non-cardiac, or not known) are 
categorised in Table 2.2. Where death could be attributed 
to the prosthesis this is also shown in Table 2.2. In 
several cases death was sudden and information from an 
autopsy was not usually available.
Reoperation for Valve Failure
Details of the 37 patients who underwent a reoperation 
for replacement of the randomised prosthesis are listed in 
Table 2.3. There was no significant difference in the 
need for valve re-replacement in patients in the three 
prostheses groups. Thrombotic obstruction was the 
commonest reason for reoperation for those receiving the 
Bjork-Shiley prosthesis, and degeneration of the cusps of
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EDINBURGH HEART VALVE STUDY. RESULTS AT FIVE YEARS 
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those receiving the porcine prosthesis. The incidence of 
periprosthetic leaks was similar in the three treatment 
groups, and in all 12 patients with this complication the 
valve was intact at operation. Endocarditis precipitated a 
second operation in four patients (two with a Bjork-Shiley 
prosthesis, and one each with a Hancock and Carpentier- 
Edwards prosthesis).
Survival
Actuarial survival curves for all patients in the 
study showed no significant differences among the three 
prostheses during seven years (mean, 5.6 years) of follow- 
up postoperatively (Figure 2.1). Actuarial survival for 
all patients was 63.2 ± 8.7% at seven years. For patients 
undergoing aortic valve replacement, actuarial survival was
69.6 ± 9.6% at seven years (Figure 2.2), for mitral valve 
replacement it was 56.7 ± 7% (Figure 2.3) and for aortic 
plus mitral valve replacement it was 62.5% ± 20.0%. There 
was no significant difference in overall survival for the 
different prostheses in any of these treatment groups. 
Thromboemboli sm
Only the first embolic event was considered in 
actuarial analysis, though 12 patients had more than one 
embolus. Eight patients with a Bjork-Shiley prostheses 
(six with mitral, one with aortic, and one with aortic plus 
mitral valve replacement) had a total of 20 embolic events. 
Two patients with Carpentier-Edwards prostheses had four 
emboli. Actuarial analysis of survival and survival free 
of embolism was performed for aortic valve and mitral valve 
replacement patients to compare the three types of
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FIGURE 2.1
Actuarial survival curves, including in-hospital mortality 
(Hosp), for all patients undergoing mitral, aortic and 
mitral plus aortic valve replacement. The numbers below 
the figure indicate the patients at risk during follow-up.













ACTUARIAL SURVIVAL ALL VALVES
(m ean 5-6 , range 3 - 8 years
r\-
Bjòrk Shiley n = (266) 
Hancock n=(107) 
Carpentier Edwards (n = 159)
Hosp 1 / 1  2 3 4
Years After Im plantation
--------266 232 221 213 195 173 124 73
.........107 89 85 80 77 72 65 57
--------159 138 133 127 123 100 64 25
FIGURE 2.2
Actuarial survival curves for patients undergoing aortic 
valve replacement with each type of prosthesis used.
Edinburgh Heart Valve Study: Results at 5 Years
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FIGURE 2.3
Actuarial survival curves for patients undergoing mitral 
valve replacement with each type of prosthesis used.
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prosthetic valves. The results among mitral valve 
replacement patients showed no significant differences in 
incidence of embolism with use of the three prostheses. A
mean of 58.5 ± 5.2% of Bjork-Shiley valve patients were
alive and 48.8 ± 9.2% were alive and free from embolism at 
seven years. For Hancock valve patients, values were 65.3 
± 7.8% and 49.3 ± 8.1% respectively, and for Carpentier- 
Edwards patients values were 46.4 ± 7.8% and 39.2 ± 8.8% 
respectively (Figure 2.4).
The incidence of embolism following aortic valve 
replacement was less than with mitral valve replacement (p 
= 0.005), and statistical analysis again showed no
differences in incidence with use of the three prostheses.
A mean 70.4 ± 6.1% of Bjork-Shiley valve patients were
alive and 66.1 ± 6.2% were alive and free of embolism after
seven years. For Hancock valve patients, values were 66.6 
± 12.1% and 56.3 ± 8.3%, respectively, and for Carpentier- 
Edwards valve patients, values were 71.9 ± 9.5% and 52.3 ± 
14% (Figure 2.5).
The relationship between use of anticoagulants and the 
incidence of thromboembolism is shown in Table 2.4. 
Because of the variable anticoagulant policy for patients 
with porcine valves during the study, the total number of 
patient-years of treatment with and without anticoagulants 
was calculated for each treatment group, and the incidence 
of embolism was expressed as a ratio of emboli per 100 
patient-years of exposure. Actuarial analysis was also 
performed. There was no significant difference in the 
incidence of embolism between those treated with and
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FIGURE 2.4
Actuarial survival and survival free from embolism for 
patients undergoing mitral valve replacement with the three 
prostheses.
Edinburgh Heart Valve Study: Results at 5 Years
THROMBOEMBOLISM : MITRAL VALVE REPLACEMENT 
  Survival ----------------Survival Free from Embolism
FIGURE 2.5
Actuarial survival and survival free from embolism for 
patients undergoing aortic valve replacement with the three 
prostheses.
Edinburgh Heart Valve Study: Results at 5 Years
THROMBOEMBOLISM : AORTIC VALVE REPLACEMENT 
 Survival --------------Survival Free from Embolism
without anticoagulants.
Factors affecting the incidence of thromboembolism 
were sought by multiple regression analysis of preoperative 
and postoperative variables. Age less than 65 years (p < 
0.01) and rheumatic etiology (p < 0.01) were associated
with embolism in patients whose aortic valves were 
replaced. For recipients of mitral valve prostheses, only 
atrial fibrillation predicted embolism (p < 0.001; Table
2.4). Overall, only 78 of 262 patients with replaced 
mitral valves remained in sinus rhythm, and eight of the 78 
had emboli. Only two patients with bioprosthetic mitral 
valve replacements and sinus rhythm had emboli.
Two patients died as a result of complications of 
anticoagulation, and a further 16 patients had significant 
complications from treatment. The number of complications 
was similar for the three prostheses, with an overall event 
rate of 1.3 per 100 patient-years.
Discussion
In this study, the randomization process resulted in 
the equal distribution of 34 preoperative clinical 
variables, many of which are known to influence early and 
late outcome following valve replacement. These include 
age, sex, valvular lesion, functional class, 
electrocardiographic evidence of left ventricular 
hypertrophy, radiographic evidence of cardiomegaly, 
pulmonary artery pressure, left ventricular end-diastolic 
pressure, and the presence of associated coronary artery 
disease. In addition, the three participating surgeons 
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The majority (88.3%) of patients available for the trial 
were included in it, with only a minority of patients 
excluded on the basis of well-defined criteria. For these 
reasons the treatment groups appeared to be well randomized 
and representative of the population studied, and any 
difference in outcome should reflect the influence of the 
prosthesis concerned.
The design of the trial was compromised by a change in 
the porcine prosthesis used (from the Hancock to the 
Carpentier-Edwards model) after 14 months. The possibility 
that time of operation might bias the results was examined 
by analysing the results of Bjork-Shiley valve replacement 
in the first 14 months and in the later part of the trial. 
No difference in results was detected, so the results of 
Bjork-Shiley valve replacement in the first 14 months and 
in the later part of the trial were combined. The change 
in prosthesis used unfortunately resulted in fewer patients 
with Hancock prostheses being followed for a longer period, 
and a larger number with Carpentier-Edwards prostheses 
being followed for a shorter period.
Actuarial survival curves showed no significant 
difference for the three prostheses either overall or for 
aortic, mitral, or aortic plus mitral valve replacements.
For patients with mitral valve replacements, atrial 
fibrillation was the only predictor of thromboembolism and 
for those with aortic valve replacements, only age less 
than 65 years and rheumatic etiology (when associated 
mitral valve disease was commonly present) predicted 
thromboembolism. There was no difference in the incidence
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of embolism with the three prostheses even though 
anticoagulation policy varied. For patients receiving 
porcine prostheses, anticoagulants were given in 19% of 
patient-years following aortic valve replacement, and in 
30% for mitral valve replacement. The effect of 
anticoagulation with porcine prostheses was difficult to 
assess because of the varying and non-randomized policy on 
anticoagulation, but there was no evidence of any 
beneficial effect with aortic valve replacement. For 
patients with a Hancock prosthesis for mitral valve 
replacement, there was a lower incidence of embolism on 
anticoagulants, but this was not statistically significant, 
possibly reflecting the smaller numbers in this group. 
There was no evidence of benefit with anticoagulation in 
patients with Carpentier-Edwards mitral valve
replacements.
The Veterans Administration Cooperative Study on Valvular 
Heart Disease
This study was designed to address two principle 
goals. The first was to compare survival and valve related 
complications between patients receiving the Bjork-Shiley 
mechanical and the Hancock porcine prostheses. The second 
was to assess the capability of a variety of clinical, 
haemodynamic, and angiographic variables to predict 
survival in patients with medically and surgically treated 
valvular heart disease, but to date no data pertaining to 
this has been published. The first aim of the study was 




All male patients undergoing valve surgery for 
replacement of a single heart valve were considered for 
entry to the randomized trial. Informed consent was sought 
from all patients and only those for whom anticoagulants 
could be given were considered eligible for the trial. As 
in the Edinburgh study randomisation took place in the 
operating theatre, if there was no surgical reason to 
prefer one type of prosthesis. Patients with active 
endocarditis were excluded. During the five year study 
period 1078 patients underwent valve replacement and 575 
who required single valve replacement were randomized. 
Results
Three hundred and ninety four patients underwent 
aortic valve replacement and 181 mitral valve replacement. 
Analysis of multiple clinical characteristics showed the 
patients to be well randomized betweend the two treatment 
groups.
Late Post-operative Deaths
Of the 531 patients leaving hospital 13 patients 
withdrew or were lost to follow-up, but survival data was 
available on all patients. The mean duration of follow-up 
was 5 years (range 3 to 8 years). There were 186 late 
deaths during this follow-up period, 88 in patients 
receiving the Hancock prosthesis and 98 in those receiving 
the Bjork-Shiley mechanical prosthesis. Of these deaths 39 




Details of the 31 patients who underwent valve 
rereplacement are shown in Table 2.5. There was no 
significant difference in the need for valve re-replacement 
in patients in the two groups. Reoperation for 
periprosthetic leak was more common after mechanical mitral 
valve replacement. In six patients undergoing aortic valve 
replacement (five who received the Hancock prosthesis) the 
randomized valve was changed at the initial operation 
because it could not be seated properly. No patient 
reguired reoperation for primary valve failure.
SURVIVAL 
Aortic Valve Replacement
There was no difference in actuarial survival between 
prostheses in those patients undergoing aortic valve 
replacement. Actuarial survival at 5 years was 72 ± 3% for 
those receiving the mechanical prosthesis and 70 ± 4% for 
those receiving the bioprosthesis (Figure 2.6).
Mitral Valve Replacement
There was a non-significant trend towards improved 
survival in patients undergoing mitral valve replacement 
with a bioprosthesis (29 deaths) compared with those 
receiving a mechanical prosthesis (40 deaths). Actuarial 
survival at 5 years was 58 ± 6% for those receiving the 
mechanical prosthesis and 70 ± 5% for those receiving the 
bioprosthesis (Figure 2.7).
Valve Related Complications
Results for survival free from any valve related 
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Veterans Administration study: actuarial survival of
patients undergoing aortic valve replacement comparing 
those receiving a bioprostheses (Bio) with those receiving 
a mechanical prosthesis (Mech). The numbers adjacent to 
the points at 2, 4 and 6 years are the numbers of patients 
available for observation at that time and the vertical 











Time (mo) 0 1 24 48 72
Bio Events 0 18 31 45 56
. o-----— o
(N = 196) Prob 1.00 .91 .84 .77 .67
Mech ,  t  Events 0 12 32 47 58










Veterans Administration study: actuarial survival of
patients undergoing mitral valve replacement comparing 
those receiving a bioprostheses with those receiving a 


















Time (mo) 0 1 24 48 72
Bio Events 0 6 20 27 28
(N = 93) Prob 1.00 .94 .78 .70 .68
Mech Events 0 8 25 33 37
(N = 88) Prob 1.00 .91 .72 .62 .52






hose dying from a different cause without having developed 
a valve related complication, were removed from the 
analysis. Where the death was clearly or possibly related 
to the prosthetic valve this was counted as a fatal valve- 
related complication. Only the first event was considered 
for actuarial analysis. in the Edinburgh study actuarial 




The total number of embolic episodes was greater in 
patients with a bioprosthesis (20 episodes) compared with a 
mechanical prosthesis (15 episodes). More patients with a 
bioprosthesis had more than one embolism and actuarial 
freedom from embolism at five years was 92 ± 2% for
patients with a mechanical prosthesis and 91 ± 2% for
patients with a bioprosthesis.
Mitral Valve Replacement
Systemic embolism occurred with egual frequency in 
both groups and actuarial freedom from embolism at five 
years was 89 ± 4% for patients with a mechanical prosthesis 
and 91 ± 3% for patients with a bioprosthesis.
Bleeding
In the total group of patients 146 episodes of 
bleeding occurred of which 17 were fatal. (In the 
Edinburgh study only 18 episodes occurred two of which were 
fatal). For patients undergoing aortic valve replacement 
actuarial freedom from bleeding was 67 ± 4% for those with 
a mechanical prosthesis and 85 ± 3% for those with a
27
bioprosthesis. For patients undergoing mitral valve 
replacement actuarial freedom from bleeding was 64 ± 7% for 
those receiving a mechanical prosthesis and 88 ± 4% for 
those receiving a bioprosthesis.
—Related Complications 
When all valve related complications i.e. bleeding, 
embolism, reoperation and bacterial endocarditis were 
considered together, there was a significant difference 
between the two prostheses for patients undergoing both 
aortic and mitral valve replacement. For aortic valve 
replacement probability of freedom from fatal or non fatal 
valve related complication at 5 years was 53 ± 4% for 
those receiving a mechanical prosthesis and 63 ± 4% for
those receiving a bioprosthesis. Corresponding figures for 
mitral valve replacement at 5 years was 45 ± 6% for those 
receiving a mechanical prosthesis, and 67 ± 5% for those 
receiving a bioprosthesis. These differences were almost 
entirely due to the difference in bleeding complications. 
Comparison between the Edinburgh and VA Trials
The patient populations enrolled in the two studies 
differed in several ways. All the patients in the VA study 
were male, but 78%, 29%, and 67% of those undergoing
mitral, aortic, and combined valve replacements 
respectively in the Edinburgh study were female. The 
Edinburgh patients were younger, less symptomatic and had a 
much lower incidence of documented coronary artery disease 
(Table 2.6). Survival and incidence of reoperation was 
similar in the two studies (Table 2.7) . An exception was 
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ral Position; seven year probability of survival 
was lower in the VA patients (42%) than in the Edinburgh 
patients (59%), Table 2.7. The major difference in results 
between the two trials was the much higher incidence of 
valve related complications in patients receiving the 
mechanical prosthesis as against those receiving the 
bioprosthesis in the VA study. This difference was almost 
entirely due to an increased risk of bleeding in patients 
receiving the mechanical prosthesis, compared with those 
receiving the bioprosthesis.
Why was the risk of bleeding so much higher in the VA 
study? The definition of bleeding in the VA study included 
all patients requiring a blood transfusion for any reason. 
This group included those with haematuria requiring 
hospitalisation and many of these patients underwent 
transurethral resection of the prostate, a common operation 
in an aging male population. Indeed, there were a total of 
40 episodes of bleeding recorded for patients with a 
bioprosthesis only half of whom were taking
anticoagulants at the time. It was possible that bleeding 
complications were more accurately recorded in the 
prospectively collected data in the VA study in which all 
patients were seen by one of the investigators, or his 
assistant, every 6 months. It was also possible that the 
therapeutic range of warfarin control in the VA study was 
too high. The protocol in the VA study specified a 
prothrombin ratio of 2.0-2.5 times the control level. In 
the USA the prothrombin time is most commonly estimated 
using commercial preparations based on rabbit brain
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thromboplastin, whereas in the UK this is based on a 
centrally standardised human brain thromboplastin which is 
more sensitive. The prothrombin ratio of 2.0-4.0 used in 
the Edinburgh study is equivalent to a ratio of 1.3-1.8 or 
2.0 in the USA, depending on the commercial reagent 
used. A therapeutic ratio of 2.0-2.5 in the USA would be 
considered excessive in the UK. This discrepancy has 
recently been appreciated in the USA (Hirsch 1987) and 
latterly the therapeutic range recommended in the VA study 
has been reduced to 1.5-2.0. Furthermore many of the 
patients in the Edinburgh Valve Trial had their 
anticoagulant control monitored at an anticoagulant clinic, 
a practice not often adopted in the USA, but one which 
appears to improve anticoagulant control (Petty et al 
1988) .
It was clear that if major differences in durability 
between prostheses was to emerge then follow-up would need 
to be extended. Complications of anticoagulant treatment 
and indeed, all episodes of bleeding needed to be recorded 
accurately for all patients rather than simply relying on 
routine clinical review. It was, therefore, decided to 
design a specific questionnaire for all surviving patients 
in the Edinburgh study to determine if any episodes of 
bleeding or blood transfusion had passed undetected by our 
usual methods of review. The results of this work up to a 
mean follow-up of 10.5 years is presented for survival and 
reoperation in Chapter 3, and for thromboembolism and 
complications of anticoagulation in Chapter 4.
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RESULTS OF THE EDINBURGH HEART VALVE TRIAL AT TEN YEARS: 
SURVIVAL AND REOPERATION
In the 1980's it became apparent that bioprosthetic 
valves might have limited durability in adult patients as 
well as in children and adolescents. Degeneration of 
bioprosthetic valves is more common six or more years after 
valve replacement (Foster et al 1987). In conseguence we 
anticipated that follow-up of patients in the Edinburgh 
trial for more than 5 years after operation might show 
differences in survival between patients with the Bjork- 
Shiley mechanical and the Hancock and Carpentier-Edwards 
bioprostheses.
Patients and Methods of Analysis
These were as described in Chapter 2. In order to be 
sure that no valve-related complications were missed a 
questionnaire was sent to all surviving patients as 
described in Chapter 4. Deaths occurring following hospital 
discharge after initial valve replacement were classified 
as "cardiac", "non-cardiac" or "possibly cardiac" on the 
basis of stated clinical data, information gathered at 
autopsy. In addition information from the death 
certificate lodged with the Registry of Deaths for Scotland 
was available for patients whose death occurred in Scotland 
(more than 90%). Deaths of those patients undergoing 
prosthetic valve replacement who died at reoperation were 
recorded as prosthesis-related deaths.
Statistical analysis was as described in Chapter 2. 
Results were analysed and presented in a manner similar to
CHAPTER 3
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those for the VA cooperative study in valvular heart 
disease; this facilitated comparison of the two studies. 
Overall survival and actuarial survival free from any of 
the valve related complications described in Chapter 2 were 
compared within the treatment groups. Only the first valve 
related complication was considered for an individual 
patient. A patient undergoing reoperation for prosthetic 
valve replacement was no longer included for other valve 
related complications but continued to be included for 
survival analysis. Patients undergoing cardiac surgery 
for reasons other than replacement of the randomised valve 
were followed for all events.
RESULTS
The treatment groups were previously shown to be well 
randomised although the randomisation process was 
potentially compromised by the change in the type of 
porcine prosthesis used after the trial had commenced. 
This introduced the possibility that the time of operation 
might bias results although it had been shown after 5 years 
of follow-up that the results of Bjork-Shiley valve 
replacement were not significantly different during the 
early and late periods of the trial. The use of two types 
of porcine bioprosthesis resulted in 107 patients receiving 
the Hancock prosthesis, and a larger group of 160 patients 
receiving the Carpentier-Edwards prosthesis who were 
followed for a shorter period of time. Analysis was 
performed for separate periods of the trial, for both 
porcine valves grouped together and for each porcine valve 
separately. The aim of the trial was to compare long-term
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results between the mechanical and porcine prostheses and 
for this reason actuarial results are presented comparing 
the Bjork Shiley prosthesis with both porcine prostheses 
considered together and also with the Hancock and 
Carpentier-Edwards prostheses considered separately.
Of the 540 patients randomised 8 received tricuspid 
valve replacement and were excluded from further analysis. 
All surviving patients were followed at least until 
September 1987. The mean duration of follow-up was 10.5 
years with a range of 7.5 to 12.5 years. Eight patients 
were lost to follow-up.
SURVIVAL 
Late post operative deaths
Of the 532 patients included for analysis 44 died 
before leaving hospital and there were 201 late deaths 
including those following reoperation. The causes of death 
(cardiac, possibly cardiac, non cardiac or not known) are 
categorised in Table 3.1. The cardiac deaths were further 
divided into those that could and could not be attributed 
to the prosthesis but since autopsy was performed on less 
than 50% of patients who died this information is 
incomplete and is not presented. Most cases of possible 
cardiac death were sudden and information from an autopsy 
was not usually available.
Actuarial Survival
All patients Analysis of actuarial survival for all
patients in the study showed no significant difference 
between those with the Bjork-Shiley, Hancock and 
Carpentier-Edwards prostheses up to 10.0 years of follow-up
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TABLE 3.1









Cardiac Death 62 52 25 27
Possible Cardiac Death 12 22 8 14
Non-cardiac Death 23 25 13 12
Not Known 2 3 1 2
Total 99 102 47 55
Total Late Deaths = 201
(Figure 3.1). This applies when the latter groups were 
considered separately and together. Actuarial survival for 
all patients was 56.5 ± 2.2% at 10.0 years.
Aortic valve replacement Analysis of actuarial survival 
for patients undergoing aortic valve replacement showed no 
significant difference between those with the Bjork-Shiley 
or the porcine prostheses whether these were considered
separately or together. Actuarial survival for all patients 
undergoing aortic valve replacement was 65.2 ± 3.3% at 10 
years (Figure 3.2)
Mitral valve replacement Analysis of actuarial survival 
for patients undergoing mitral valve replacement showed no 
significant difference between those with the Bjork-Shiley 
or the porcine prostheses whether these were considered
together or separateley. Actuarial survival for all 
patients undergoing mitral valve replacement was 50.1 +
3.2% at 10 years (Figure 3.3).
Mitral and aortic valve replacement
Analysis of actuarial survival for patients undergoing
combined mitral and aortic valve replacement showed no
significant difference between those with the Bjork-Shiley 
or the porcine prostheses considered separately or 
together, but this subgroup comprised only 60 patients.
Late post operative events
Thromboembolism, bleeding requiring hospitalisation or 
transfusion, bacterial endocarditis and reoperation for 
prosthetic valve replacement were all considered 
significant events. Reoperation is discussed in this 
chapter and the other events are discussed m  chapter 4.
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Actuarial survival for all patients undergoing valve 
replacement.
FIGURE 3.1
Edinburgh Heart Valve Study: Results at 10 Years
SURVIVAL BY VALVE TYPE
FIGURE 3.2
Actuarial survival for patients undergoing aortic valve 
replacement.
Edinburgh Heart Valve Study: Results at 10 Years
SURVIVAL BY VALVE TYPE
years from operation
FIGURE 3.3
Actuarial survival for patients undergoing mitral valve 
replacement.
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SURVIVAL BY VALVE TYPE
REOPERATION
Seventy patients have undergone reoperation to replace 
the randomised prosthetic valve; 17 with the Bjork-Shiley, 
and 53 with porcine prostheses (20 with Hancock and 33 with 
Carpentier-Edwards prostheses). Sixteen patients
undergoing reoperation died before hospital discharge. Of 
the 54 patients successfully undergoing reoperation 16 have 
subsequently died. Reoperation was significantly more 
freguent after porcine aortic valve replacement and porcine 
mitral valve replacement. When the two types of porcine 
prostheses were considered separately reoperation was 
significantly more freguent after Hancock aortic valve 
replacement and Carpentier-Edwards mitral valve 
replacement. These differences were almost exclusively due 
to reoperation reguired because of leaflet failure of the 
porcine valves occurring more than five years after 
implantation (Table 3.2). Of the eleven patients who had 
undergone combined aortic and mitral valve replacement with 
Hancock or Carpentier-Edwards prostheses nine required 
reoperation because of leaflet failure; the aortic 
prosthesis had failed in 2 patients, the mitral in 5 and 
both prostheses had failed in 2 patients.
Actuarial analysis
Degeneration of porcine prostheses might be gradual 
and failure of a mechanical prosthesis might be abrupt and 
catastrophic (Taylor 1988). The number of patients 
undergoing reoperation for failure of a porcine prosthesis 
in this study might possibly have been offset by a similar 




suddenly due to prosthetic failure. Therefore, we examined 
actuarial survival free from reoperation and from all 
classifications of cardiac death to determine if there was 
a difference in the rate of occurrence of prosthetic valve 
failure.
Actuarial Survival Free From Reoperation Or Cardiac Death 
All— Patients. Actuarial survival free from reoperation or 
cardiac death showed a significant difference favouring the 
Bjork-Shiley prosthesis when compared with both porcine 
prostheses considered together (p=0.02), and when the 
Hancock and Carpentier-Edwards prostheses were considered 
separately (p=0.05) (Figure 3.4).
Aortic Valve Replacement
Actuarial survival free from reoperation or cardiac 
death for the subgroup of patients undergoing aortic valve 
replacement was not different when patients receiving the 
Bjork-Shiley prosthesis were compared with those receiving 
the Hancock or Carpentier-Edwards porcine prostheses 
considered together. If these latter groups were 
considered separately there was a higher actuarial survival 
free from reoperation or cardiac death in those receiving 
the Carpentier-Edwards prosthesis than those receiving the 
Bjork-Shiley prosthesis, but this did not reach statistical 
significance (p = 0.07) (Figure 3.5).
Mitral Valve Replacement
Actuarial surivival free from reoperation or cardiac 
death for the subgroup of patients undergoing mitral valve 
replacement was higher for patients receiving the Bjork- 
Shiley prosthesis compared with those receiving a porcine
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FIGURE 3.4
All patients undergoing valve replacement: actuarial
survival with any classification of cardiac death or 
reoperation as the end point.
Edinburgh Heart Valve Study: Results at 10 Years
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years from operation
FIGURE 3.5
Patients undergoing aortic valve replacement: actuarial
survival with any classification of cardiac death or 
reoperation as the end point.
Edinburgh Heart Valve Study: Results at 10 Years
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years from operation
prosthesis but this did not reach statistical significance 
(p 0.06). When those receiving the Carpentier-Edwards 
and the Hancock prosthesis were considered separately there 
was a significant difference between those receiving the 
Bjork-Shiley prosthesis and those receiving the Carpentier- 
Edwards prosthesis (p = 0.02) but not those receiving the 
Hancock prosthesis (Figure 3.6).
Discussion
We have shown no difference in survival after a mean 
of 10.5 years of follow-up in patients receiving the 
Bjork-Shiley mechanical prosthesis and those receiving a 
Hancock or Carpentier-Edwards prosthesis in a large 
randomised prospective trial.
There was however a significant difference in the need 
for reoperation due to the increased incidence of porcine 
valve failure which occured five or more years after 
implantation. Mechanical valve failure can on occasions 
occur suddenly causing death before the patient can be 
brought to surgery. In a few instances death was sudden
and shown to be caused by prosthetic valve obstruction.
In most instances of sudden death an autopsy was not
performed and in many cases death was attributed to 
myocardial infarction. Some of these cases may have been 
due to sudden failure of the prosthetic valve. Failure of 
bioprosthetic valves is usually gradual and the patient is 
likely to come to reoperation and this may be the reason 
that more patients with bioprosthetic valves came to
reoperation. To determine if this was the case we analysed 
actuarial survival free from reoperation and from all
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FIGURE 3.6
Patients undergoing mitral valve replacement: actuarial
survival with any classification of cardiac death or 
reoperation as the end point.
SURVIVAL FREE FROM REOPERATION OR CARDIAC DEATH BY VALVE TYPE
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years from operation
cardiac deaths. There was a significant difference in 
actuarial survival free from reoperation or cardiac death 
favouring those who received the Bjork-Shiley prosthesis 
when all patients undergoing valve replacement were 
considered. There was also a significant difference 
favouring the Bjork-Shiley prosthesis compared with the 
Carpentier-Edwards prosthesis for patients undergoing 
mitral valve replacement. For patients undergoing aortic 
valve replacement there was no significant difference in 
actuarial freedom from reoperation or cardiac death between 
those receiving the different prostheses. This indicates 
that the failure rate of the porcine valves was indeed 
significantly higher with the possible exception of those 
undergoing single aortic valve replacement.
Reoperation for failure of bioprosthetic valves was 
more common for those used in the mitral rather than the 
aortic position. Furthermore, in patients with both mitral 
and aortic bioprostheses when reoperation for valve failure 
was required it was twice as common for the mitral 
prosthesis to have failed. This is in agreement with 
findings previously noted by others (Bolooki et al 1983, 
Warnes et al 1983).
There appeared therefore to be a significant advantage 
to the Bjork-Shiley prosthesis with a lower incidence of 
late prosthetic failure and the need for reoperation when 
compared to the porcine prostheses. This advantage 
occurred most noticeably in patients undergoing mitral 
valve replacement, especially those in whom the Carpentier- 
Edwards prosthesis was used.
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The main advantage of porcine prostheses is the lack of 
need for long-term anticoagulant treatment with the 
attendant risks of bleeding. The occurrence of bleeding 
and the other valve related events, embolism and bacterial 
endocarditis are presented in the next Chapter.
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RESULT OF THE EDINBURGH HEART VALVE TRIAL AT 10 YEARS 
VALVE RELATED COMPLICATIONS
In Chapter 3 we observed no difference in overall 
survival between patients undergoing valve replacement with 
a porcine or Bjork-Shiley mechanical valve prosthesis, but 
there was a noticeably increased risk of reoperation for 
those patients receiving porcine valve replacements 
compared with those receiving mechanical valve 
replacements. in this Chapter we consider complications 
that might have arisen in patients after their valve 
replacement operations in addition to reoperation; these 
include embolism, bleeding and complications with 
anticoagulants, and bacterial endocarditis. A brief review 
of the occurrence of embolism in association with valvular 
heart disease is given, and the occurrence of this and 
other valve related complications in patients in the 
Edinburgh heart valve trial is presented.
Embolism
It has long been established that there is an 
association between valvular heart disease and systemic 
embolisation. This association is strongest with mitral 
valve disease, especially in patients who have developed 
atrial fibrillation (Casella et al 1964; Coulshed et al 
1970). Patients with mitral stenosis and in sinus rhythm 
remain at risk of systemic embolisation; at least 20% of 
emboli noted in 3 major series occurred in patients in 
sinus rhythm (Szekely 1964; Coulshed et al 1970; Fleming 
and Bailey 1971). Recently, it has been shown by
CHAPTER 4
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ambulatory monitoring that more than half of patients 
with mitral stenosis who are in sinus rhythm may have 
intermittent episodes of atrial arrhythmias which may be 
asymptomatic (Ramsdale et al 1987). Thrombus in various
stages of organisation is frequently found in the left 
atrium in patients undergoing surgery for mitral valve 
disease (Ellis and Harken 1961). The development of
thrombus in the left atrium has been thought to be due to 
stagnation of blood flow and the formation of eddy currents 
within an enlarged left atrium, which might be exacerbated 
by the diminished cardiac output common with mitral 
stenosis (Askey and Bernstein 1960).
There may be some diminution in size of the left 
atrium following mitral valve replacement but it commonly 
remains enlarged and we have observed significant left 
atrial enlargement was present in most patients who had 
undergone mitral valve replacement alone, or in combination 
with aortic valve replacement (see Chapter 6).
Clinical Manifestations of Systemic Emboli
Large emboli causing stroke, or major damage to other 
organs or limbs produce obvious effects. Small emboli may 
cause no symptoms. It is common to find evidence of 
previous embolisation at autopsy in the kidneys of patients 
with valvular heart disease (Hoxie and Loggin 1940). The 
two organs in which small emboli are likely to cause 
symptoms are the brain and the retina, manifested as 
transient neurological deficit and amaurosis fugax. Such 
episodes may not be recorded at routine follow-up of 
patients with prosthetic valves attending for annual
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McGoon (1984) noted the wide discrepancy in the 
incidence of systemic emboli following valve replacement, 
reported in several large series of patients. In reviewing 
the methods by which data was collected in 51 reported
series he found that in many series specific information 
about possible episodes of embolism was not sought and 
information about anticoagulant treatment and the guality 
of its control was often omitted. Only rarely was follow-up 
data collected prospectively. The studies in which 
specific data was sought prospectively tended to report the 
higher incidence of systemic emboli and McGoon suggested 
specific guidelines for the collection of data related to 
embolism.
We have followed these guidelines and guestions 
designed to detect any episode of embolism were included in 
the questionnaire which was sent, at two separate times of 
follow-up, to all surviving patients in the Edinburgh valve 
study. If an embolic episode was suspected from the 
patient's response to questionnaire then further 
information was sought from the patient directly and from 
his general practitioner.
Bleeding and Complications of Anticoaqulation
The major risk of prolonged systemic anticoagulation 
with warfarin is haemorrhage. Since the introduction of 
warfarin in 1941 its effects on various mechanisms in the 
clotting system have been elucidated, but the complete 
basis of the antithrombotic action of warfarin has not been 
fully understood. As Wessel and Gitel (1984) have noted 
"the dosage (of warfarin) was regulated according to the
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prothrombin time, which predicted bleeding, rather than 
according to assays that demonstrated antithrombosis".
As discussed in Chapter 2 there was considerable 
difference m  the thromboplastin used as the basis for 
testing the prothrombin time between the USA and the UK 
which, until recent times, has meant that patients treated 
with warfarin in the USA have been receiving higher doses 
than patients in the UK (Hirsch 1987; Lancet Editorial
1987). We have said that this could account for some of the 
discrepancies noted in the incidence of bleeding in the VA 
and the Edinburgh 5 years studies summarised in Chapter 2.
Other studies from the USA have not reported such a 
high incidence of haemorrhage as that noted in the VA 
study. Cohn reported on a series of 912 patients 
undergoing valve replacement surgery in Boston (also one of 
the larger geographical centres participating in the VA 
study) contemparaneously with those patients enrolled in 
the VA study. In Cohn's series the risk of haemorrhage was 
1.82% per patient year, almost identical to the Edinburgh 
trial, but much lower than that of the VA study (6.6% for 
patients with the aortic mechanical prosthesis, 3.0% for 
patients with the aortic bioprosthesis, 7.2% for patients 
with the mitral mechanical prosthesis, and 2.4% for 
patients with the mitral bioprosthesis (Cohn 1984).
We have also noted that two other explanations for the 
discrepancy in rates of bleeding between the Edinburgh and 
VA studies could be due to differences in the definition of 
bleeding and also under-reporting of bleeding episodes in 
the Edinburgh study. Bleeding in the VA study was
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essentially defined as an episode requiring hospitalisation 
or blood transfusion, but also included "gross haematuria 
leading to hospitalisation or urologie manipulation". In 
the aging male population studied there this included those 
undergoing prostatectomy whereas more than half of the 
patients enrolled in the Edinburgh study were female 
(Chapter 2). in the Edinburgh study we had not included 
clinical events requiring blood transfusion or haematuria 
unless these were related to anticoagulant treatment. To 
facilitate comparison of results in the two studies for 
later follow-up of patients, we therefore, amended the 
later questionnaire sent to all survivors and clearly 
defined bleeding as any episode necessitating blood 
transfusion or hospitalisation and asked patients to report 
any episodes of bleeding, or blood transfusion which had 
occurred at any time since their operation.
Bacterial Endocarditis
Bacterial endocarditis was recorded if suspected 
clinically, or found at reoperation, or autopsy.
Statistical analysis
Statistical analysis of results was performed as 
described in Chapter 3.
RESULTS
Embolism
There were a total of 113 episodes of embolism 
recorded in 91 patients. Fifty-nine embolic events 
occurred in 42 patients with Bjork-Shiley prostheses (28 
undergoing mitral, 10 undergoing aortic and 4 mitral plus 
aortic valve replacement). Fifty four emboli occurred in
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patients with porcine prosthesis. Twenty-three embolic 
events occurred in 20 patients with Hancock prostheses (11 
undergoing mitral, 8 aortic and 1 mitral plus aortic valve 
replacement); 31 embolic events occurred in 29 patients 
with Carpentier-Edwards (16 undergoing mitral, 9 aortic and 
4 mitral plus aortic valve replacement). Thirty-eight 
emboli resulted in residual neurological deficit of which 5 
were fatal (Table 4.1).
Bleeding
Bleeding occurred on 52 occasions in 44 patients; on 
34 occasions in 28 patients with Bjork-Shiley and on 18 
occasions in 15 patients with porcine prostheses, (on 12
occasions in 11 patients with Hancock, and on 6 occasions
in 5 patients with Carpentier-Edwards prostheses) (Table
4.1). In five patients bleeding was fatal. Only a small 
number of episodes of bleeding that had not previously
been noted were reported as a result of the questionnaire. 
The majority of these were minor and did not result in
transfusion or hospitalisation. Patients were not taking 
anticoagulants prior to the episode of bleeding on 4 
occasions in patients with the Hancock prosthesis and on 
two occasions in patients with the Carpentier-Edwards 
prosthesis. Anticoagulant control was known to be poor 
prior to 6 episodes of bleeding and was unknown prior to 12 
episodes of bleeding. Bleeding was significantly more 
frequent in those with Bjork-Shiley prostheses.
Bacterial Endocarditis
Bacterial endocarditis occurred on 25 occasions in 19 
patients and it occurred twice in six patients.
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FATAL AND NON-FATAL EVENTS FOLLOWING VALVE REPLACEMENT
TABLE 4.1
Numbers of patients (events)
Bjork Porcine Hancock Carpentier
(n=266) (n=266) (n=107) (n=159)
Eïnboli 42(59) 49(54) 20(23) 29(31 )
Fatal or with residua 17 20 11 9
B le e d in g  28(34) 15(18) 10(12) 5(6)
Endocarditis 10(12) 9(13) 2(3) 7(10)
R e o p e r a t i o n  17 53 20 33
Total no Patients 95 126 52 74
Total no Events 120 138 58 80
Endocarditis occurred on 12 occasions in 10 patients with 
Bjork Shiley prostheses and on 13 occasions in 9 patients 
with porcine prostheses, (on 3 occasions in 2 patients with 
Hancock, and on 10 occasions in 7 patients with 
Carpentier-Edwards prostheses) Table 4.1. Five patients 
were successfully treated medically and seven died without 
reoperation. Seven patients underwent reoperation with one 
operative death. Only five patients out of the eleven who 
were successfully treated medically or surgically remain 
alive.
ACTUARIAL EVENT-FREE SURVIVAL
Actuarial analysis of event-free survival is presented 
to the occurrence of first valve-related event (re­
operation, embolism, bleeding and bacterial endocarditis) 
or death.
All patients
Analysis of actuarial event-free survival for all 
patients showed a trend towards improved event-free 
survival with the Bjork-Shiley prosthesis compared with 
both porcine prostheses grouped together up to 10.0 years 
of follow-up (p = 0.07) and when the Hancock or Carpentier- 
Edwards prosthesis were considered separately (p = 0.15)
(Figure 4.1).
Aortic valve replacement
Actuarial event-free survival for patients undergoing 
aortic valve replacement showed no significant difference 
in event-free survival in those receiving the Bjork-Shiley 
prosthesis compared with those receiving the Hancock or 
Carpentier-Edwards prosthesis either when these were
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FIGURE 4.1
All patients undergoing valve replacement: actuarial
survival with death or any event (reoperation, bleeding, 
embolism, endocarditis) as the end point.
Edinburgh Heart Valve Study: Results at 10 Years
EVENT FREE SURVIVAL BY VALVE TYPE
years from operation
considered as a combined group or considered separately 
(Figure 4.2).
Mitral valve replacempnt-
Actuarial event-free survival for patients undergoing 
mitral valve replacement showed a non-significant trend 
towards improved event-free survival for those receiving 
the Bjork Shiley prosthesis compared with those receiving 
the Hancock or Carpentier-Edwards prosthesis when both 
porcine prostheses were considered as a combined group ( p
0.13) and when considered separately (p = 0.27) (Figure 
4.3) .
Discussion
We have not observed a significant difference in 
event-free survival between patients receiving the Bjork- 
Shiley mechanical prosthesis and those receiving a 
bioprosthetic valve. Bleeding occurred more frequently in 
those receiving the Bjork-Shiley prosthesis as would be 
expected as all patients with this prosthesis received 
anticoagulants. This was more than offset however by the 
significantly increased need for reoperation in those 
receiving the Hancock and Carpentier-Edwards porcine 
prostheses as noted in Chapter 3.
The net result was a trend towards improved event-free 
survival, but this did not reach statistical significance. 
It is possible that if a larger number of patients had been 
enrolled in the study this trend would have reached 
statistical significance. It is also possible that with a 
more prolonged period of follow up more patients will 
require reoperation and a significant difference in event-
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Patients undergoing aortic valve replacement: actuarial
survival with death or any event as the end point.
FIGURE 4.2
Edinburgh Heart Valve Study: Results at 10 Years
EVENT FREE SURVIVAL BY VALVE TYPE
years from operation
FIGURE 4.3
Patients undergoing mitral valve replacement: actuarial
survival with death or any event as the end point.
Edinburgh Heart Valve Study: Results at 10 Years
EVENT FREE SURVIVAL BY VALVE TYPE
years from operation
free survival will develop.
We have made rigorous efforts to record all valve 
related events and have used a definition of bleeding and 
embolism similar to those used in the VA study. After a 
mean follow up period of 10.5 years how do our results now 
compare to those of the Veterans Administration Co­
operative Study at 5 years? in the V A study 575
patients were entered into a prospectively randomised study 
comparing the Bjork-Shiley with the Hancock prosthesis in 
patients undergoing single valve replacement. After a mean 
of 5 years of follow-up there was no difference in survival 
between the two groups. There was a significantly greater 
actuarial freedom from valve-related events in those 
receiving the Hancock prosthesis whether in the aortic or 
mitral position. This difference was due to a much higher 
incidence of bleeding in those receiving the Bjork-Shiley 
prosthesis; there being no patients reguiring reoperation 
for valve failure due to cusp disruption in those receiving 
the Hancock prosthesis. In the VA study 209 episodes of 
bleeding were recorded in 575 patients followed-up for a 
mean of 5 years. By contrast our study recorded only 59 
episodes of bleeding in 532 patients followed-up for a mean 
of 10.5 years. There are several possible explanations 
for these differences.
Firstly the definition of bleeding in the VA study 
required this to be severe enough to lead to 
hospitalisation or blood transfusion, as in the Edinburgh 
study. The VA study also included blood transfusion during 
elective surgery which inevitably led to the recording of
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more episodes of 'bleeding'.
ndly, the differences could have occurred due to
differences in the populations study. The patients in the
VA study were exclusively male and many required 
prostatectomy and associated transfusion. The population 
in the VA study may also have been less meticulous about 
their anticoagulant control.
Thirdly the proportion of patients with porcine 
prostheses who were prescribed anticoagulants could have 
differed• The proportion of patients with bioprostheses in 
the VA study who received anticoagulants is not stated, but 
in our study the total number of patient years on 
anticoagulants was 327 with 1341 patient years on no
anticoagulants. It is possible that a higher proportion of
patients in the VA study received anticoagulants.
Fourthly the degree of anticoagulation between the two 
studies was different as previously discussed in Chapter 2. 
We used a prothrombin ratio of 2.0 - 4.0 which is
equivalent to a prothrombin ratio of 1.3 to 2.0 with 
commercially available reagents used in the USA. A 
prothrombin ratio of 2.0 - 2.5 used in the VA study would 
be considered excessive in the United Kingdom and this 
could further explain the differences in the rates of 
significant bleeding reported in the two studies. Indeed, 
latterly in the VA study the recommended prothrombin ratio 
was reduced to 1.5 to 2.0 for these reasons.
In the light of the results reported in Chapter 3 and 
above what recommendations can be made for the selection of 
type of prosthesis for patients requiring valve
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replacement? This data analysis suggests that patients who 
because of atrial fibrillation or for other reasons would 
normally continue anticoagulants after valve replacement 
should receive a mechanical prosthesis. In our practice 
this would include the majority of patients undergoing 
replacement of the mitral valve. Such patients should have 
warfarin controlled at a prothrombin ratio of 2.0 - 4.0
which is equivalent to a ratio of 1.3 - 2.0 in the USA.
There is no apparent clear advantage for the use of a 
mechanical prosthesis in those undergoing aortic valve 
replacement, but younger patients could benefit from a 
mechanical prosthesis of proven mechanical durability. 
Patients in whom anticoagulants must be avoided could 
receive a bioprosthesis although this might necessitate 
further operation at a later date.
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NON INVASIVE METHODS OF ASSESSING NATIVE STENOTIC VALVES
Methods for non-invasive assessment of prosthetic 
valves have been derived from methods for assessing the 
function of native and diseased valves. As all prosthetic 
valves, however well designed, are intrinsically stenotic, 
the non-invasive methods of assessment of stenotic lesions 
of native aortic and mitral valves are reviewed in this 
Chapter. The single most accurate non-invasive method 
currently available are Doppler ultrasound techniques and 
these are covered in some greater detail in the latter part 
of the Chapter and in Chapter 6.
As with all medical investigations, non-invasive
physical measurements are complementary to and must be used 
in conjunction with clinical evaluations; the clinical 
observations most relevant to the assessment of stenosis 
are identified below.
Systolic Time Intervals
The most important physical signs in determining the
severity of aortic stenosis are a delayed rise and
increased duration of the carotid upstroke, a late peak to 
the systolic murmur, and a softness of the second heart 
sound. These characteristics have also been used in the 
quantitative measurements from phonocardiographic recording 
of the murmur and analysis of the carotid pulse trace. 
Thus Voelkel et al (1980) found that the time between the 
onset of electrical activity of the QRS complex of the 
electrocardiogram and the peak intensity of the aortic 
systolic murmur (the Q to murmur peak) was increasingly
CHAPTER 5
prolonged in patients with increasingly severe aortic 
stenosis. The pre-ejection period (PEP) i.e. the time from 
the inscription of the QRS complex to initial upstroke of 
the carotid pulse, and the left ventricular ejection time 
(LVET) i.e. the time taken for mechanical systole, also 
alter in aortic stenosis. The ratio of PEP/LVET falls in 
severe aortic stenosis. Voelkel et al found that systolic 
time intervals and phonocardiography could separate most 
patients into those with or without severe aortic stenosis, 
but they could not guantify the severity more accurately.
In left ventricular failure, the LVET falls and in 
patients with very severe aortic stenosis and conseguent 
impairment of left ventricular function, the assessment of 
the severity of aortic stenosis from systolic time 
intervals is unreliable (Gardin et al 1980). In patients 
with mitral stenosis analysis of the apex cardiogram has 
been used to estimate the rate of left ventricular filling 
in early diastole, which is diminished in mitral stenosis. 
Phonocardiography can be used to measure the interval 
between aortic valve closure and mitral valve opening which 
is reduced in mitral stenosis. Both methods are of limited 
accuracy and now only of historical interest (Bloomfield et 
al 1985).
Electrocardiography
The electrocardiogram may accurately detect the 
presence of left ventricular hypertrophy, which is an 
almost invariable pathological association with severe 
aortic stenosis, but the prevalence of co-existing coronary 
artery disease and hypertension in adult patients with
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aortic stenosis mean that such ECG changes are not specific 
for the presence of severe aortic stenosis. Plain chest 
radiography may provide pointers to the presence of both 
aortic and mitral stenosis, but provides only a rough guide 
to the severity of the lesion.
Aortic Stenosis
Echocardiography can much more accurately detect and 
quantify aortic stenosis. Left ventricular wall thickness 
can be measured directly and as the degree of left 
ventricular hypertrophy is related to overall wall stress, 
this can be used to estimate left ventricular systolic 
pressure by the formula devised by Bennett et al (1975). 
Systolic intraventricular pressure (kPa) =
30 x wall thickness (cm)
left ventricular transverse diameter (cm)
Aortic pressure can be estimated from blood pressure 
obtained by sphygmomanometer and peak to peak gradient
across the aortic valve obtained by subtraction. (The 
conversion factor from kPa to mmHg is 7.5)
Bennett's formula has proved to be highly accurate in 
quantitating left ventricular pressure, and thus the 
severity of aortic stenosis in children, but in adult
patients in whom hypertrophy can develop with associated
conditions the correlation is poorer. Similarly in
children and young adults, direct visualisation of the 
aortic valve by two dimensional echocardiography can 
determine whether the valve has a normal configuration with 
three cusps, or is abnormal with two, or even one cusp.
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Congenitally stenotic aortic valves tend to be fused at 
commisures of the cusps and to form a dome-shape in 
y Only by imaging the whole of the valve cusps by
two dimensional echocardiography can the size of the true 
orifice be determined. Weyman et al (1977) have shown that 
the maximum separation of the tips of the aortic valve 
cusps can accurately determine the size of the aortic 
orifice as determined by cardiac catheterisation. M mode 
echocardiography which can determine only one single 
dimension of the valve may be highly inaccurate as the 
separation of the cusps imaged by the single ultrasound 
beam may be taken at the base of the leaflets, leading to 
an erroneously large estimation of the aortic valve 
orifice.
In adult patients direct visualisation of the aortic 
valve leaflets produces much less accurate results because 
fibrosis and calcification of the aortic valve leaflets 
leads to greatly enhanced ultrasound reflectance and 
consequent reverberation of the ultrasound signal, which 
makes the measurement of the separation of two points, that 
is the valve cusps much less accurate. De Maria et al 
(1980) found that two dimensional echocardiography was a 
very sensitive method of detecting valvular aortic 
stenosis. All of their patients with severe aortic 
stenosis had a cusp separation of 11 mm or less and 92% of 
them had a cusp separation of 8 mm or less. The 
specificity of these values for identifying patients with 
moderately severe stenosis was, however, poor and 65% of 
patients with moderately severe aortic stenosis had a cusp
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separation of greater than 8 mm. Similar results have been 
reported by others (Godley et al 1981).
Mitral Stenosis
M mode echocardiography has been used to guantify the
severity of mitral stenosis from direct measurements of the
mitral valve (Segal et al 1966 , Shiu 1977 ) and by 
measurements of the rate of left atrial emptying (Strunk et 
al 1977), and left ventricular filling (Hall et al 1979), 
both of which are affected by stenosis of the mitral valve. 
Direct measurement of the mitral valve orifice by two 
dimensional echocardiography has been shown to be a highly
accurate measure of mitral valve area when correlated with
measurements made at cardiac catheterisation, and direct 
measurements made at the time of surgery (Henry et al 1975, 
Nichol et al 1977) .
Ultrasound Assessment of Stenotic Valves using the Doppler 
Principle
The Doppler technique uses the principle that the 
velocity of an object moving away from an observer (or 
receiver) can be determined by the change in freguency of 
waves of known freguency transmitted from, or reflected 
from the moving object. Doppler's principle was initially 
used to determine the speed with which stars were moving 
away from, or towards Earth by the colour of the light they 
transmitted to Earth. The principle is egually applicable 
to ultrasound and the velocity of blood can be determined 
by the change in freguency of ultrasound waves reflected 
from the blood corpuscles according to the eguation.
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(transmitted frequency) x cosine of intercept angle 
where V is blood velocity of blood cells, C is the speed of 
ultrasound through the body, F is the change in frequency 
of transmitted ultrasound. The cosine of 0° is 1 and that 
of 180 is 1 and therefore to minimise the effect of small
changes in the angle of the ultrasound beam on measurement 
of blood velocity, this angle should be kept as close as 
possible to 0°. Within 20° degrees of 0°, the magnitude of 
of measured velocity will be reduced by only 6%, but as the 
intercept angle becomes larger than 20°, the magnitude of 
the recorded velocity drops sharply and is more sensitive 
to changes in angle.
Measurement of Pressure Drop Across a Stenotic Valve
The Bernoulli equation can be used to describe the 
pressure drop (P1 -P2 ) across a stenotic valve.
P]_-P2 = l/2p (V2 2 - Vi2) + j2 dv/dt x ds + R(v)5
where p expresses mass density of a fluid, V2 = peak 
Doppler velocity beyond the stenosis, V]_ = peak Doppler
velocity proximal to the obstruction, dv/dt x ds = change 
in velocity/change in time x change in distance, R(v) = 
viscous resistance of the vessel x local velocity. 
Combining p for blood with factors that convert gradient to 
mmHg and velocity to m/s, the coefficient for blood is 
3.98 which is usually rounded to 4.0. The second term of 
the equation (flow acceleration) applies during valve 
opening and closing when the gradient measurement is not 
clinically relevant. The third term (viscous friction) has 
been shown to be unimportant in vitro and in vivo and the
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equation can thus be conveniently shortened to Px - P2 = 4 
(V22 - V]2)
Recent work with sophisticated in vitro experiments 
have investigated the validity of the modified Bernoulli 
equation. Redquarth et al (1984) and Holen et al (1985) 
have compared pressure gradient measured in vitro models 
that had fluid containing particulate matter passing 
through a chamber that allowed placement of interchangeable 
orifices. Correlation between Doppler calculated pressure 
drop, using the modified Bernoulli equation, and that 
measured directly was very good.
Usually maximal velocity proximal to a stenotic 
orifice is less than 1 m/sec and can be ignored without 
loss of accuracy of the assessment; this further shortens 
the equation considerably to:
Pi - P2 = 4 V22
The simplicity of the modified Bernoulli equation and 
the accuracy with which it can be applied to blood flow 
across a stenotic orifice have led to its widespread use in 
clinical cardiology. The application of this principle has 
been facilitated by the development of fast Fourier 
transformation of the Doppler signal so that a spectral 
analysis of the signal can be displayed and in this way the 
highest velocities more easily identified. The method has 
proved more accurate than the use of a maximal frequency 
estimator when measuring high velocities. This is 
important in aortic stenosis in which very high velocities 
occur and in which the signal to noise ratio may be lowest 
at the highest velocities, those which are most important
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for calculation of the gradient across the valve.
Measured— Doppler— Pressure Gradients and their Comparison 
with those Derived at Cardiac Cqtheterisation
Holen et al ( 1976 , 1979 ) applied the modified
Bernoulli equation in measuring transvalvular pressure 
gradient in patients with mitral stenosis. They showed 
good correlation in mean pressure gradient measured 
simultaneously by both cardiac catheterisation and the 
Doppler method. The gradient determined by the modified 
Bernoulli equation is an instantaneous measurement and has 
no direct equivalent to measurements made at cardiac 
catheterisation. There is an inherent delay in peak aortic 
pressure which occurs after peak left ventricular pressure, 
even when the two are measured simultaneously by two 
separate catheters in the left ventricle and aorta. 
Folland et al (1984) have shown that this is accentuated if 
peripheral artery pressure is used to substitute for 
central aortic pressure. The peak pressure gradient 
calculated from the Doppler velocity profile is the peak 
instantaneous pressure gradient which has not been used in 
the assessment of aortic stenosis by ca 
catheterisation. The peak left ventricular to peak aortic 
pressure is easily measured at catheterisation and most 
commonly used in clinical practice, but there is no direct 
equivalent measurement which can be derived from Doppler 
docity profiles. Furthermore, the peak aortic pressureveJ
in elderly patients, with severeiy stenotic valves may be
high because of lack of compliance in the aorta and
nr-pcsure difference . , a. it is the mean pressurearterial tree. it
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throughout systole which most accurately reflects the true 
degree of obstruction to ejection of blood from the left 
ventricle m  aortic stenosis. This is derived from 
measuring the area between simultaneously obtained (or less 
accurately superimposed) left ventricular and aortic 
pressure traces divided by the duration of systole. The 
only measurement made at cardiac catheterisation and by 
Doppler ultrasound which is directly comparable is mean 
pressure gradient (Allen et al 1988).
It has been suggested that this mean pressure gradient 
can be obtained from the Doppler velocity profile by 
measuring its area and dividing by its duration to obtain 
mean velocity, and using the modified Bernoulli equation to 
calculate mean pressure gradient. In the modified 
Bernoulli equation, however, there is a squared 
relationship between velocity and pressure at any one 
instant, and the true mean pressure gradient should be 
calculated from the sum of an infinite number of 
instantaneous measurements along the Doppler velocity 
profile. In practice this can be approached by calculating 
instantaneous pressure at 10 msec intervals and averaging 
these to derive mean pressure thus 
P = 4[ (Vi)2 + (V2)2 + (V3)2 + (Vn)2]
Where Vi = velocity at 10 msec, V2 = velocity at 20 msec 
etc.
Manual calculation of this formula is impractical and 
to be applicable in clinical use the calculation is done by
computer.
In many of the earlier papers evaluating the use of
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Doppler ultrasound in the assessment of aortic stenosis, 
comparison was made between the peak instantaneous pressure 
gradient derived from Doppler measurements, and the peak to 
peak gradient obtained at catheterisation. Hatle et al 
(1980), Stamm and Martin (1983), Berger et al (1984) and 
Simpson et al (1985) in small series of patients all showed 
a reasonably good correlation between these measurements. 
It was observed by others that there was frequently "over­
estimation of the peak instantaneous pressure gradient 
measured by the Doppler technique and peak to peak pressure 
gradient measured at catheterisation (Kratchek et al 1985). 
Hegrenaes and Hatle (1985) subsequently also reported that 
in a larger series of patients with aortic stenosis the 
peak instantaneous pressure gradient measured by Doppler 
was consistently higher than the peak to peak pressure 
gradient measured at cardiac catheterisation. The mean 
pressure gradient derived from the Doppler measurements by 
using the integrated equation above correlated very closely 
with mean pressure gradient measured at catheterisation.
Currie et al (1985) reported a series of 100 
consecutive patients with aortic stenosis at the Mayo 
Clinic who underwent trans-septal catheterisation with 
direct measurement of left ventricular pressure and aortic 
pressure and simultaneous continuous wave Doppler 
measurement of aortic blood velocities. They found a very 
close correlation between mean pressure gradient measured 
by the two techniques. They also observed that m  
comparing peak instantaneous pressure gradient measured by 
Doppler with peak to peak pressure gradient at
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catheterisation the greatest disparity occurred at the 
lowest mean pressure gradients. m  practical terms this 
could lead to patients with mild aortic stenosis being 
diagnosed as having a more severe lesion if the Doppler 
derived data were only loosely interpreted (Yeager et al
1988). it might also be expected to lead to difficulties 
m  accurately measuring the small gradients that typically 
occur with prosthetic valves.
Thus it has been shown in a number of well conducted 
studies that measurement of aortic blood velocities in 
aortic stenosis can provide data about the pressure 
difference as accurately as that obtained by the most 
precise (and most invasive) cardiac catheterisation 
methods.
The measurement of gradient alone however, is not 
enough to quantify the degree to which the valve is 
stenosed i.e. the reduction in valve area as the gradient 
for any specific valve area must obviously be dependent on 
the flow across the valve, the cardiac output.
Assessment of Valve Area using Doppler Measurement
Three approaches have been used to calculate valve 
area from Doppler derived data by making some estimate of 
cardiac output. The time required for the left 
atrioventricular pressure gradient to decrease to half of 
its maximal early diastolic value, the pressure half-time 
was orginally used with catheterisation data. Libanoff and 
Rodbard (1968) noted that the pressure half-time could be 
used as an estimate of mitral valve area and was relatively 
independent of changes in cardiac output, heart rate or the
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degree of regurgitation. Hatle et al (1979) derived the 
pressure half-time from Doppler measurement of transmitral 
blood flow. Using the modified Bernoulli eguation (P = 
4V2) they defined the Doppler half-time as the time for 
transmitral velocity to fall from its peak by a factor of 
the sguare root of 2. Hatle and Angelsen subsequently 
related mitral valve area to Doppler half-time using an 
empirical constant:
Mitral valve area (cm2) = 220 / pressure half-time (msec)
Stamm and Martin (1983) confirmed the validity of this 
method in a series of 30 patients. Bryg et al (1986) found 
that, apart from slight discordance between mitral valve 
area measured by this Doppler technique and by cardiac 
catheterisation depending on whether the patient was in 
sinus rhythm or atrial fibrillation there was good 
correlation between the two measurements. Smith et al 
(1986) found that mitral valve area measured by Doppler 
method correlated well with catheterisation data for 
patients with unoperated mitral stenosis, but less well for 
those who had previously undergone mitral valvotomy.
Warth et al (1984) obtained cardiac output invasively 
using a thermodilution Swan Ganz catheter, mean aortic 
valve gradient obtained by Doppler and calculated valve 
area from the Gorlin formula. They compared results 
obtained in this way with those at cardiac catheterisation 
and found an excellent correlation. Cardiac output can 
also be measured by Doppler methods combined with two 
dimensional echocardiography. The amount of blood ejected 
from the heart with each beat, the stroke volume can be
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calculated by multiplying the cross-sectional diameter of 
the aorta by the time velocity integral of blood velocities 
obtained from this area by pulsed Doppler measurements. A 
good correlation has been shown by several investigators 
between calculations of cardiac output made from 
measurements derived from the pulmonary artery or aorta, 
and those made by invasive means (Magnin et al 1981 and 
Goldberg et al 1982). Such measurements are particularly 
useful for recording a change in cardiac output in the same 
patient as the cross-sectional area of the aorta or 
pulmonary artery remains the same. This method is not as 
accurate for the absolute measurement of cardiac output, 
mainly because of errors in the measurement of aortic or 
pulmonary cross-sectional area. Furthermore, abnormalities 
of the aortic valve may invalidate such measurements based 
on the size of the aortic root.
The second approach to measuring effective area of the 
mitral and aortic valves which has recently been described 
uses the continuity equation. This states simply that 
laminar flow through a conduit is equal to the mean 
velocity times the cross-sectional area of the conduit. 
With flow remaining constant the ratio of cross-sectional 
areas at two different sites is inversely proportional to 
the ratio of the respective mean velocities.
Q = AX VX = A2 V2 
Where Q is flow, Ai is the cross sectional area of a normal 
part of the heart, Vx is mean velocity through Ax, A2 is 
the cross-sectional area of the stenosis and V2 is the me 
velocity of blood through A2.
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If A]_, V]_ and V2 are known then A2 , the stenotic area, 
can be derived. In practice Vx is measured by pulsed wave 
Doppler in the left ventricular outflow tract and A 2 is the 
cross-sectional area of the left ventricular outflow tract 
measured by two dimensional echocardiography. Measurements 
of aortic valve area by this method were proposed by Zoghbi 
et al (1986) and have been subsequently validated by Oh et 
al (1988). The continuity equation has similarly been used 
for estimation of mitral valve area by Nakatani et al 
(1988). These methods of assessing the degree of stenosis 
of a valve by using the continuity equation and Doppler 
ultrasound techniques are the most accurate non-invasive 
techniques yet devised.
NON INVASIVE ASSESSMENT OF PROSTHETIC VALVES
Left ventricular hypertrophy may or may not regress 
following aortic valve replacement and the measurement of 
hypertrophy by ECG or echocardiography is unhelpful in 
assessing the function of aortic valve prostheses. 
Systolic time interval measurement has not proved useful in 
assessing prosthetic valves. Evaluation of rigid component 
prostheses by both M-mode and two dimensional 
echocardiography is limited because all the components of 
the prosthetic valve are highly reflective of ultrasound; 
unless the transducer beam is appropriately directed, the 
motion of the ball disc or tissue leaflets may be obscured 
by echoes from these surrounding structures. As an aid to 
the diagnosis of prosthetic malfunction Brodie et al (1976) 
used combined phonocardiography and echocardiography to 
measure the precise intervals between aortic valve closing,
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and the mitral valve opening, but this only detected 
markedly abnormal prosthetic function. The leaflets of 
porcine prosthetic valves can usually be well imaged by two 
dimensional echocardiography.
The leaflets may appear thickened with prosthetic 
stenosis and with infective endocarditis (Alam et al 1979, 
Shapira et al 1979, Effron and Popp 1983). These findings 
however are relatively non-specific and may be found with 
normally functioning older prostheses (Alam et al 1983). 
Prolapse or rupture of the leaflets of bioprosthetic is 
often seen with severely regurgitant prostheses (Alam et al 
1983, McComb et al 1984). However, two dimensional 
echocardiography has not facilitated estimation of subtle 
changes in bioprosthetic valve function.
Doppler Assessment of Prosthetic Valve Function
In theory the use of the modified Bernoulli equation 
should also be applicable to the evaluation of prosthetic 
valves. Flow patterns across prosthetic valves are, 
however, fundamentally different from those found normally, 
with further variation between types of prosthesis. Flow 
through porcine prosthetic valves might be expected to be 
similar to that through native valves, but flow beyond 
mechanical valves would be expected to be considerably 
different with semi-central flow in tilting disc valves and 
peripheral flow with ball and cage valves.
The modified Bernoulli equation as described above is 
applicable to flow across prosthetic valves if three
conditions are fulfilled.
(1) Flow must be incompressible, i.e. the density
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of blood does not change.
(2) low must be frictionless, i.e. pressure loss 
due to viscous resistance is negligible.
(3) Flow velocities must be measured along 
streamlines of the flow.
The first condition can be considered true at 
pressures found within the heart. With respect to the 
second condition flow through a prosthetic valve may occur 
through irregularly shaped orifices, thus creating 
significant viscous resistance. Thirdly, flow through a 
prosthetic valve may not be parallel to the streamlines of 
flow especially for valves with tilting or moving parts.
Yoganathan et al (1978, 1984, 1986) have performed
flow visualisation studies of fluid passing through St Jude 
and Bjork-Shiley mechanical valves and the Carpentier- 
Edwards porcine valve. They used a laser light source and 
added tracer particles to the fluid to obtain photographs 
of flow patterns beyond the prostheses, and showed that 
with all prostheses flow was principally streamlined. 
Their studies of porcine valves indicated that their flow 
stream is indeed central and similar to that through human 
aortic valves.
Have these theoretical problems interfered with the 
measurement of pressure gradients across prosthetic valves? 
In vitro Studies
Teirstein et al (1985) measured pressure gradients by 
continuous wave Doppler and by direct manometric 
measurement across a variety of irregular and multiple 
stenoses. They used an in vitro model to simulate the left
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ventricular outflow tract, and used heparinized blood as 
the fluid medium. An excellent correlation was found 
between mean pressure gradient derived by Doppler and 
manometric methods. Similar results using similar 
experimental designs have been found by Wong et al (1985) 
and Redquarth et al (1984).
In vivo Studies
Holen et al (1979, 1981) have demonstrated a very good 
correlation between mean gradient measured by Doppler and 
simultaneously recorded by cardiac catheterisation in 
patients with recently implanted Bjork-Shiley and Hancock 
valves. Wilkins et al (1986) studied 12 patients with both 
mechanical and porcine prosthetic mitral or tricuspid 
valves which were thought to be stenotic. They performed 
simultaneous continuous wave Doppler and cardiac 
catheterisation measurements using direct measurement of 
atrial and ventricular pressure by transseptal 
catheterisation or direct left ventricular puncture. There 
was a highly significant correlation (r= 0.96) between mean 
pressure gradient measured by Doppler and manometric 
methods. The measurement of peak instantaneous pressure 
gradient by Doppler also correlated well with peak 
instantaneous pressure gradient measured by simultaneous 
catheterisation in all three of these studies.
Wilkins et al also compared valve area calculated by 
cardiac catheterisation using the Gorlin formula to that 
obtained by the methods described by Hatle (and Angelsen 
1982) and Holen et al (1979, 1981). Hatle's method
derives valve area by dividing the pressure half-time
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derived from the Doppler trace by an empirical constant. 
H d e n  s method derives valve area from the cardiac output 
measured at catheterisation and the velocity of blood 
flowing across the valve derived from the Doppler tracings. 
Correlation of prosthetic valve area derived by the Gorlin 
and Doppler methods was very poor. This might be expected 
on theoretical grounds because the Gorlin equation assumes 
a relationship between velocity of blood across a stenotic 
orifice (which cannot be measured at catheterisation), and 
the measured pressure difference. The method of Holen 
measures velocity directly from the Doppler traces. 
Wilkin's found the correlation between the two Doppler 
methods was better (r= 0.73) than between the Doppler 
method and catheterisation method.
These results confirm that as in patients both with 
native stenotic valves and prosthetic valves the 
measurement of mean pressure gradient across prosthetic 
valves by Doppler is highly accurate. Measurements of peak 
instantaneous pressure gradient were also highly accurate 
and are the easiest measurement to make from the spectral 
waveform of a Doppler signal. Although this measurement is 
not used in catheterisation data it is widely used in 
Doppler analysis. For these reasons I decided to use the 
measurement of mean pressure gradient and peak 
instantaneous pressure gradient in comparing the 
haemodynamic performance of Bjork-Shiley and porcine 
prosthetic valves implanted a decade previously in the 
patients enrolled in the Edinburgh heart valve trial. It 
would be preferable to have some measure of effective valve
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area in comparing the performance of these prostheses. The 
methods based on the continuity equation would not be 
applicable to all patients enrolled in the valve study as 
many had disease of native valves or had more than one 
valve replaced which prevented proper application of the 
continuity equation. Furthermore, although methods based 
on the continuity equation had been described they had not 
been widely validated in 1986 when I commenced this study. 
At that time the only method which had been widely used and 
validated was the method of Hatle (1979) using pressure 
half-time. For this reason I decided to employ this as a 
measure of effective valve area in patients with mitral 
valve prostheses; the results of these investigations are 
presented in the next chapter.
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COMPARISON USING DOPPLER ECHOCARDIOGRAPHY OF HAEMODYNAMIC 
PERFORMANCE OF THE BJORK-SHILEY AND PORCINE PROSTHESES ONE 
DECADE AFTER IMPLANTATION
The haemodynamic performance of Bjork-Shiley and 
porcine prostheses have not so far been compared several 
years after implantation. Khuri et al (1988) reported a 
haemodynamic comparison of the Bjork-Shiley and Hancock 
prostheses in half of the patients enrolled in the VA 
Cooperative valve study investigated six months after 
implantation. They showed a small advantage to the Bjork- 
Shiley prostheses when used in the aortic position but no 
difference in the mitral position. Other studies of 
haemodynamic function had also largely been done shortly 
after implantation of the prosthesis (Bjork et al 1973, 
Lurie et al 1977, Cotter and Miller 1979, Thormann et al 
1981, Horskotte et al 1983, Gray et al 1984). Lipson et al 
(1982) have reported a deterioration in haemodynamic 
performance of porcine prostheses used in the mitral 
position. Eighteen patients were studied by cardiac 
catheterisation six months post operatively and at an 
average of 7 years after surgery. Over this period the 
average value of mean pressure gradient rose from 5.9 ± 0.7
mmHg to 8.6 ± 0.7 mmHg.
The patients in the Edinburgh valve study provided an 
excellent opportunity to compare haemodynamic performance 
of these prostheses 8 - 12 years after implantation and
Doppler echocardiography as described in Chapter 5 provided 
an accurate method of assessing the haemodynamic
CHAPTER 6
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performance non-invasively. In consequence, the aim of 
this study was to measure the haemodynamic performance of 
Bjork-Shiley and porcine prosthetic valves approximately 
one decade after implantation and to assess any significant 
difference in performance occasioned by their use over this 
period of time.
Patients
All surviving patients enrolled in the Edinburgh heart 
valve study were considered for Doppler examination. In 
July 1988 of the 532 randomised patients analysed in the 
Edinburgh valve trial there were 241 survivors who had not 
undergone further valve replacement or been lost to follow 
up. Approximately two thirds of the patients had originally 
been referred from the Western General Hospital and 
followed-up by the cardiologists at that hospital or 
associated peripheral clinics in Stirling, Kirkcaldy and 
Inverness. Patients had been enrolled in the study from 
John 0'Groats (one patient!) in the north to Whitehaven in 
Cumbria in the south. Doppler ultrasound equipment is only 
available at the Royal Infirmary and patients attending for 
routine review underwent a Doppler examination there, 
either at a routine clinic visit, or by separate 
appointment. A total of 52 aortic valve prostheses and 50 
mitral valve prostheses were examined in 96 patients. 
Doppler signals adequate for analysis were recorded across 
47 of the aortic prostheses and all of the mitral 
prostheses. In the majority of patients with mitral 
prostheses the size of the prosthesis was 33 mm, but a 
minority of patients had smaller or larger prostheses
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(Table 6.1). Prostheses of a variety of sizes had been 
implanted in patients undergoing aortic valve replacement 
(Table 6.1), but the distribution of sizes between those 
with Bjork-Shiley and porcine prostheses was similar. 
Methods
All Doppler examinations were performed by either 
myself or Miss Ann Colthart, chief physiological 
measurement technician, in a standard manner, with a 
Hewlett-Packard ultrasonograph model 7700. Doppler 
examinations performed by other staff were not considered 
because differences in technigue can lead to recording of 
suboptimal Doppler traces, which although adeguate for 
diagnostic work, would be unsuitable for analysis of small 
differences of performance of individual valves.
All patients underwent a complete two dimensional 
echocardiographic examination in the left lateral decubitus 
position. M-mode recordings of maximal left ventricular
dimensions were made from the body of the left ventricle 
from the parasternal short axis view, and those of the left 
atrium from the parasternal long axis view. Doppler
recordings were made from the apex or left axilla in
patients with mitral prostheses. Both pulsed wave and 
continuous wave Doppler recordings were made with
adjustment of transducer position, so that an optimal audio 
signal including the highest frequencies was obtained.
Patients with mitral valve prostheses were also asked
to undergo a treadmill exercise test with full 12 lead
monitoring. They were exercised using the Naughton 3 mph
test which maintains a constant treadmill speed of 3 mph
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TABLE 6.1
numbers q f patients examined with each size cf prosthetic valve
ACRTIC VALVE REPLACEMENT
Bjork-Shiley Porcine
29 mm 2 1
27 mm 9 3
25 mm 5 7
23 mm 6 10
21 mm 2 2
19 mm 1 0
Not known 0 1
Total 25 22
MURAL VALVE REPLACEMENT
35 mm 0 2
33 mm 29 11
31 mm 5 3
Total 34 16
and increases the slope of the treadmill by 2% every two 
minutes starting from a baseline of 0%. if patients could 
not manage a speed of 3 mph this was reduced to 2 mph but 
the slope increments increased as before. Patients were 
exercised to limiting symptoms of dyspnoea or fatigue. 
Immediately on ceasing exercise they were transferred to an 
examination couch and Doppler recordings repeated as before.
For patients with aortic prostheses only continuous 
wave recordings were made as aliasing of the signal 
occurred with pulsed wave Doppler at blood velocities found 
with these prostheses. The transducer was placed at the 
apex or left axilla in the left lateral position, at the 
right sternal edge in the right lateral position, and in 
the subcostal area, or in the suprasternal notch in the 
semi-recumbent position in all patients. The transducer 
was angulated in each position to record the optimal audio 
signal incorporating the maximal frequencies which could be 
obtained. These techniques were necessary to ensure that 
the Doppler ultrasound beam was travelling as close as 
possible to the direction of blood flow through the 
prosthetic valve. Recordings were made on the stereophonic 
audio channels of a Sony Betamax video tape recorder. 
Spectral analysis of the Doppler signal was recorded 
simultaneously on the video channel of the video recorder 
and also on hard copy using the dedicated Honeywell strip 
chart recorder.
Analysis of Doppler Wave Forms 
Audio Signal
The audio signals were played back through the
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spectral analyser of a Doptek continuous wave Doppler 
ultrasound machine. This system has a 20 second memory and 
playback loop, with facilities for outlining the spectral 
wave form using a light pen system interfaced with the TV 
monitor (Figure 6.1). The wave forms thus outlined can be 
transferred to a BBC microcomputer for analysis (Figure
6.2). At least 3 consecutive waveforms for patients in 
sinus rhythm and at least 5 consecutive waveforms for those 
in atrial fibrillation were analysed. Variation in the 
intensity of the Doppler signal with respiration occurred 
in some patients, precluding analysis of this number of 
consecutive beats. If this problem occurred then a similar 
number of non-consecutive beats were analysed. If possible 
all waveforms from the 20 second playback loop were 
analysed.
Computer Analysis of Audio Waveforms
Peak velocity of the audiosignal was calculated at 10 
msec intervals along the waveform using the Doppler 
equation as described previously. The point of maximal 
velocity was identified from the waveform. The upslope of 
the waveform was calculated as the rate of rise from the 
initial inscription of the waveform to maximal velocity. 
The pressure half-time was calculated as the time taken for 
the velocity of the waveform to fall from its maximal point 
to the point where velocity was equal to maximal velocity 
divided by the square root of two. If this velocity was 
not achieved the downslope was extrapolated to enable 
calculation of the pressure half-time. Peak— instantaneous 
pressure gradient was calculated from maximal velocity
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FIGURE 6.1
Top panel: Doppler signal obtained from a patient with a
mijr£Lu va prosthesis. The patient is in sinus rhythm
an there are therefore two peaks to the wave form, the 
rePresenting pressure filling and the second atrial 
filling. Lower panel: the same Doppler waveform has been
drawn around with the light pen system and is outlined by a faint line.
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ENTERS PRINTS DUMPB EXITS 
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FIGURE 6.2
The outline of Doppler waveforms from 
beats have been transferred to the BBC 
beginning of each waveform is flagged 







using the modified Bernoulli equation. Mean pressure 
gradient was calculated as the arithmetic mean of 
instantaneously derived pressure calculated at 5 msec 
intervals along the Doppler waveform according to the 
formula given previously. For purposes of comparison mean 
gradient was also calculated from the formula:
Mean pressure gradient (mmHg) = 4(V)2
where V is mean velocity obtained from measurement of the 
area under the waveform. The values of peak velocity 
measured in this way (from two sample wave forms) were 
compared with those calculated from the spectral display 
of the Hewlett-Packard system recorded on the video channel 
for simultaneously recorded individual waveforms obtained 
from each patient.
Computer Analysis of Waveforms Recorded on Hard Copy
Peak velocity was derived for all waveforms from hard 
copy recordings by manual measurement. Similarly, pressure 
half-time was calculated manually from a selection of 
waveforms for comparison with those obtained by computer 
analysis. Computer analysis of waveforms recorded on hard 
copy was done by two methods. Firstly the hard copy 
recordings were transferred to a video monitor using a 
television camera; this permitted some magnification of 
the wave form to facilitate the tracing of the outline of 
the waveform. A tracking rollerball was used to move a 
cursor on the TV monitor around the outline of the 
waveform, and to highlight the points of calibration for 
measurement of velocity and the speed at which the copy was 
recorded. The waveforms were then transferred to a BBC
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microcomputer for anfllvoioanalysis using the programme as
mentioned above.
isSecondly a commercially developed computer analys 
system was used (Sonotron/Diasonics) . This system is 
designed to facilitate the analysis of hard copy recordings 
using a magnetic graphics pad and "gunsight mouse" 
interfaced with an IBM PC microcomputer. The hard copy 
recordings from the Hewlett Packard strip chart recorder 
were made on silver-backed paper which interfered with 
proper functioning of the graphics pad. This probl em was 
overcome by photocopying the original recordings and 
analysing the photocopied traces. For copyright reasons 
the programme for this system was not available for 
detailed inspection. The method quoted for calculation of 
mean pressure gradient was that of Otto et al (1986) and 
was similar to that used in our own programme. Results of 
analysis of the same waveform using both methods were 
compared and found to be in excellent agreement. This was 
reassuring but to be certain that no small measured 
difference in the performance of the different types of 
prosthesis were due to unrecognised variation in the 
methods of analysis, the comparison of the different types 
of prosthesis was made using only the same method of 
analysis. The method based on the BBC programme was used 
for comparison of the mitral prostheses and the 
Sonotron/Diasonics programme are for comparison of aortic 
prostheses.
Statistical Analysis
The measurements were analysed using "Epistats , a
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computer software statistical package designed for analysis 
of small data sets and suitable for use with the IBM PC 
microcomputer. The paired and unpaired t test was used to 
assess the differences in the means of continuous variables 
for paired and unpaired samples. The Pearson correlation 
coefficient was calculated for analysis of linear 
regression.
Comparison of Hewlett Packard and Doptek Spectral Analysis 
of Doppler Signal
The spectral profiles produced by the spectral 
analyser of the Hewlett Packard and Doptek machines were 
compared by recording known velocities in a pump simulator 
by the method of McDicken (1986). The velocities recorded 
by each machine were identical across a range of velocities 
up to a maximal velocity of 2 m/s.
Comparison was made between the maximal recorded 
velocities estimated by the Doptek spectral analyser from 
the Doppler signal recorded on the audio channel of the 
video tape recorder and the simultaneously displayed 
spectral profile recorded on the video tape recorder. For 
patients with mitral prostheses the correlation was good. 
Peak velocity recorded by both systems differed by less 
than 10%. There was one limitation in that exact 
measurement of peak velocity was difficult to calculate 
from the velocity profiles as recorded on the video channel 
because of the small size of the velocity profile and the 
limited scale (only 1 m/sec intervals) displayed on the 
video screen. In all cases the audio Doppler signal was 
strong and spectral display was clearly defined on both
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Hewlett Packard and Doptek systems.
In marked contrast the spectral display of maximal 
velocities from patients with aortic prostheses was poor 
with the Doptek spectral analyser when the audio signal was 
weak. Maximal velocities were poorly defined and an 
increase in overall gain often led to an increase in noise 
level and a poor spectral envelope. The strength of the
Doppler signal at maximal velocities was usually weaker
for aortic prostheses as compared with mitral prostheses. 
This problem was exacerbated by the recording of the 
Doppler signal from some patients with aortic prostheses at 
a low recording level on one of the stereo channels of the 
video cassette recorder.
For these reasons it was preferred that Doppler 
spectral velocity signals from patients with aortic 
prostheses were recorded on hard copy direct from the 
Hewlett-Packard ultrasound machine and the data then 
analysed as outlined above; for ease of use I employed the 
Sonotron/Diasonics analysis system based on the IBM PC 
computer. Doppler signals obtained from flow across mitral 
prostheses were analysed with the computer software based 
on the BBC computer usually from the audio channel 
recordings and without the need for a hard copy record.
One unsuspected result in the Hewlett-Packard spectral 
analysis of the Doppler signal was seen in patients with 
Bjork-Shiley mechanical prostheses where the spectral 
velocity profile was affected by the "clicks of the 
mechanical prosthesis. The Doppler signal was freguently 
attenuated for up to 50 msec after the "opening click" of
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the prosthesis. An example of this phenomenon is shown in 
Figure 6.3. and it is probably due to the spectral 
analyser having an automatic gain compensation so that gain 
is reduced for a period of time following a very strong 
audiosignal (such as that created by the opening of the 
prosthetic disc). in practice it had little effect on the 
delineation of the spectral velocity profile but it proved 
impossible to identify the upslope (rate of rise) of the 
signal and therefore the measurement could not be used in 
any comparative analyses.
RESULTS - OBSERVATIONS ON MITRAL VALVE PROSTHESES 
Measurements of Left Atrial and Left Ventricular Dimensions 
by M Mode Echocardiography
M Mode echocardiographic recordings suitable for 
analysis were obtained in 45 of 50 patients with mitral 
prostheses . There was no statistically significant 
difference in chamber sizes between patients with porcine 
and those with Bjork-Shiley prostheses (Table 6.2). The 
mean fractional shortening was 27% ± 9% in those with
porcine prostheses and 31% ± 8% in those with Bjork-Shiley 
prostheses, a difference not statistically significant. 
Fractional shortening was less than 25% (indicating 
significant depression of left ventricular function) in 5 
patients with porcine prostheses (17%, 19%, 19%, 21% and
22%) and in 4 patients with Bjork-Shiley prostheses (15%, 
16%, 23% and 24%).
Measurement of Mean Pressure Gradients— from— Doppler
Recordings
C a l c u l a t i o n  o f  m e a n  p r e s s u r e  g r a d i e n t  w a s  d o n e  b y  t h e
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FIGURE 6.3
mitr-al otltained from a patient with a Bjork-Shiley
nr f n  ? i? hesis. The part of the Doppler spectral 
?c fol.lc™ ±̂ (3 the opening click (OC) of the prosthesis
fpv, i nU-a 6 ^  ^tomatic gain compensation system.
The closing click is seen at the end of the Doppler spectral profile.
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MEAN LEFT ATRIAL AND LEFT VENTRICULAR DIMENSIONS IN PATIENTS WITH 
MITRAL VALVE REPLACEMENT
Bjork-Shiley Porcine
Left atrial dimension (mm)
Mean 54 55
SD 10 9
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two methods described previously, by integration of 
multiple calculations of instantaneous pressure made at 5 
msec intervals along the Doppler velocity profile and by 
calculating the average velocity and from this deriving 
mean pressure gradient. Mean pressure gradient calculated 
by integration was, as anticipated, consistently higher 
than that calculated from average velocity. The mean 
pressure gradient across porcine mitral prostheses was 3.4 
± 1.4 mmHg calculated by the integration method and 2.6 ± 
1.2 mmHg calculated by the method using average velocity. 
The equation describing the relationship was:
Mean pressure gradient by integration method (mmHg) = 1.11 
x mean pressure gradient from average velocity + 0.45 
mmHg
There was a close correlation between the two values 
(r = 0.98) .
This relationship is shown in Fig 6.4.
In patients with Bjork-Shiley mitral valve prostheses 
the mean pressure gradient calculated by the integration 
method was 3.0 ± 1.3 mmHg, and 2.4 ± 1.2 mmHg calculated by 
the method using average velocity. The equation describing 
the relationship was:
Mean pressure gradient by integration method (mmHg) - 1.04 
x mean pressure gradient from average velocity + 0.64 mmHg 
There was a close correlation between the two values (r 
0.98) .
This relationship is shown in Fig 6.5.
The calculation of mean pressure gradient by the 
integration method is theoretically more valid and was
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FIGURE 6.4
Comparison of mean pressure gradient in mmHg derived from 
the average velocity (Av grad), and that derived by 
integrating the values obtained for instantaneous velocity 
at 10 msec intervals along the Doppler spectral profile 
(Int grad) for patients with porcine mitral valve 
prostheses.
PORCINE MITRAL PROSTHESES: MEAN GRADIENT DERIVED 









Comparison of mean pressure gradient in mmHg derived from 
the average velocity (Av grad), and that derived by 
integrating the values obtained for instantaneous velocity 
at 10 msec intervals along the Doppler spectral profile 
(Int grad), for patients with Bjork-Shiley mitral valve 
prostheses.
BJORK SHILEY MITRAL PROSTHESES: MEAN GRADIENT 
DERIVED FROM AVERAGE VELOCITY AND FROM 
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consistently higher than that calculated from average 
velocity. The former calculation of mean pressure gradient 
has in consequence been used throughout the remainder of 
this chapter.
Comparison— of— Mean and Peak Instantaneous Pressure
Gradients
There was a weak correlation between mean pressure 
gradient peak and instantaneous pressure gardient in 
recordings from patients with porcine and Bjork-Shiley 
mitral valve replacements. The correlation coefficient for 
the two measurements for patients with porcine mitral valve 
replacements was 0.78 and 0.62 for patients with Bjork- 
Shiley mitral valve replacements.
Comparison of Pressure Gradients Across Mitral Prostheses 
of Different Sizes
There was a wide variation in the mean pressure 
gradient measured across mitral prostheses of the same 
size. This is best illustrated by the range of mean 
pressure gradients measured across the 33 mm Bjork-Shiley 
prosthesis. There were 29 patients with this size of 
prosthesis, the largest single group of patients with one 
size of prosthesis incorporated in this study. The lowest 
mean pressure gradient was 1.57 mmHg and the highest 6.70 
mmHg in the group. Mean pressure gradients for prostheses 
of different sizes are depicted in Figure 6.6. There was 
overlap of values between the groups and for purposes of 
comparison of the prostheses these groups were amalgamated.
There was similarly a wide variation in £eak 
instantaneous pressure gradient measured across mitral
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FIGURE 6.6
M e a n  p r e s s u r e  g r a d i e n t  m e a s u r e d  a t  r e s t  a c r o s s  B j o r k - S h i l e y  
a n d  p o r c i n e  m i t r a l  v a l v e  p r o s t h e s e s  o f  d i f f e r e n t  s i z e s .


















31mm 33mm 31mm 33mm 35mm 
Diameter of prostheses
prostheses of the same size with considerable overlap 
between groups.
Comparison of Pressure Gradient across Biork-Shilev and
Porcine Mitral Prostheses
The mean pressure gradient for all patients with 
Bjork-Shiley prostheses was 3.0 ± 1.2 mmHg and was 3.4 ± 
1.4 mmHg for patients with porcine prostheses (Figure 6.7).
The mean peak instantaneous pressure gradient for 
patients with Bjork-Shiley mitral prostheses was 9.0 ± 2.4 
mmHg and 8.9 ± 3.2 mmHg for those with porcine mitral
prostheses. These values were not significantly different 
(Figure 6.8).
Comparison of Pressure Half-Time of Biork-Shilev— and 
Porcine Mitral Prostheses
T h e r e  w a s  a  l a r g e  r a n g e  o f  p r e s s u r e  h a l f - t i m e  
m e a s u r e m e n t s  i n  p a t i e n t s  w i t h  p r o s t h e s e s  o f  t h e  s a m e  s i z e  
i l l u s t r a t e d  b y  t h e  r a n g e  f o r  33 mm B j o r k - S h i l e y  m i t r a l  
p r o s t h e s e s  w h i c h  v a r i e d  f r o m  67 t o  182 m s e c  ( F i g  6.9). 
T h e r e  w a s  c o n s i d e r a b l e  o v e r l a p  b e t w e e n  p r o s t h e s e s  o f  
d i f f e r e n t  s i z e s  ( F i g  6.9). W h e n  a l l  B j o r k  S h i l e y  
p r o s t h e s e s  w e r e  c o n s i d e r e d  t o g e t h e r  m e a n  p r e s s u r e  h a l f - t i m e  
w a s  87 ± 28 m s e c  c o m p a r e d  t o  114 ± 36 m s e c  f o r  p o r c i n e
m i t r a l  p r o s t h e s e s ,  a  d i f f e r e n c e  w h i c h  w a s  s t a t i s t i c a l l y  
s i g n i f i c a n t  ( p  = 0.05) ( F i g u r e  6.10).
Results of exercise studies
S e v e n t e e n  p a t i e n t s  w i t h  B j o r k - S h i l e y  a n d  e i g h t  
p a t i e n t s  w i t h  p o r c i n e  p r o s t h e s e s  s u c c e s s f u l l y  c o m p l e t e d  a n  
e x e r c i s e  t e s t  w i t h  a d e q u a t e  r e c o r d i n g s  o f  t h e  m i t r a l  
D o p p l e r  s i g n a l  m a d e  a f t e r  e x e r c i s e .  I n  t w o  p a t i e n t s
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Mean values (+SD) of mean pressure gradient at rest across 
Bjork-Shiley and porcine mitral valve prostheses.
MEAN GRADIENT ACROSS MITRAL PROSTHESES (MEAN + SD)
FIGURE 6.7










Mean values (+SD) of peak instantaneous pressure gradient 
at rest across Bjork-Shiley and porcine mitral valve 
prostheses.
PEAK INSTANTANEOUS PRESSURE ACROSS MITRAL PROSTHESES



















P r e s s u r e  h a l f - t i m e  m e a s u r e d  a t  r e s t  a c r o s s  B j o r k - S h i l e y  a n d  
p o r c i n e  m i t r a l  v a l v e  p r o s t h e s e s  o f  d i f f e r e n t  s i z e s .
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FIGURE 6.10
Mean values (±SD) of pressure half-time at rest across 
Bjork-Shiley and porcine mitral valve prostheses.
















*  p = 0-05
the Bjork-Shiley prostheses and one with a porcine 
prosthesis a Doppler signal adequate for quantitative 
analysis could not be recorded after exercise. Three 
patients could not manage to exercise on the treadmill and 
the remainder did not wish to attempt treadmill exercise. 
Effect— of— Exercise on Mean Gradient across Mitral 
Prostheses
The mean of the mean pressure gradient for those 
patients with Bjork-Shiley prostheses who successfully 
completed an exercise test was 2.9 ± 0.7 mmHg at rest and 
increased significantly (p = 0.01) to 4.0 ± 1.5 mmHg
immediately after exercise (Fig 5.11). The mean of mean
pressure gradient for those patients with a porcine mitral
prosthesis was 3.0 ± 1.0 mmHg at rest and increased
significantly (p = 0.01) to 4.1 ± 1.5 mmHg immediately
after exercise (Fig 6.11).
Effect of Exercise on Pressure Half-time of Mitral 
Prostheses
The mean of pressure half-time for patients with 
Bjork-Shiley mitral prostheses who successfully completed 
an exercise test was 98 ± 28 msec at rest and was not
significantly different at 91 i 30 msec immediately after 
exercise (Fig 6.12). The mean of pressure half-time for 
patients with porcine mitral prostheses was 127 ± 27 msec
at rest and fell significantly (p = 0.05) immediately after 
exercise to 97 ± 22 msec (Fig 6.12).
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FIGURE 6.11
Mean pressure gradient at rest and on exercise for patients 
with Bjork-Shiley and porcine mitral valve prostheses. 
Mean values at rest and on exercise are also shown.
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Pressure half-time at rest and on exercise for patients 
with Bjork-Shiley and porcine mitral valve prostheses. 
Mean values at rest and on exercise are also shown.
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RESULTS - OBSERVATIONS ON AORTIC VALVE PROSTHESES 
Measurement of Left Ventricular Dimensions by M Mode 
Echocardiography
M mode echocardiographic recordings suitable for 
analysis were obtained in 40 of 52 patients with aortic 
prostheses. The mean left ventricular end diastolic and 
end systolic dimensions of patients with porcine prostheses 
were higher than in patients with Bjork-Shiley prostheses 
(Table 6.3). Mean fractional shortening was similar at 35% 
in those with porcine prostheses and 38% in those with 
Bjork-Shiley prostheses (Table 6.3). Three patients with 
porcine valve prostheses had fractional shortening below 
25% (18%, 19% and 23%).
Comparison of Mean and Peak Instantaneous Pressure 
Gradients
Mean and peak instantaneous pressure gradients were 
calculated for each patient with one exception where the 
Doppler signal initially thought to be adeguate could not 
be used for quantitative analysis. Mean pressure gradient 
correlated closely with peak instantaneous pressure 
gradient in recordings from patients with porcine and 
Bjork-Shiley aortic valve replacements. For patients with 
porcine aortic valve replacements the correlation 
coefficient between the two measurements was 0.93. The 
relationship between the two measurements was described by
the equation:
Mean pressure gradient (mmHg) = 0.46 x peak instantaneous
pressure gradient + 1.3 mmHg (Fig 6.13).
For p a t i e n t s  w i t h  B j o r k - S h i l e y  a o r t i c  v a l v e
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TABLE 6.3
mean left ventricular dimensions and FUNCTION IN PATTTNTS wrm acrtic
VALVE REPLACEMENT
Bjork-Shiley Porcine













Comparison of mean pressure gradient (mean press) and peak, 
instantaneous pressure gradient (peak press) for patients 
with Bjork-Shiley aortic valve replacements.
FIGURE 6.13
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replacements the correlation coefficient between the two 
measurements was 0.96. The relationship between the two 
measurements was described by the equation:
Mean pressure gradient (mmHg) = 0.49 x peak instantaneous 
pressure gradient +0.9 mmHg (Fig 6.14).
Comparison— of Pressure Gradients across Prosthetic Valves
of Different Sizes
There was a wide range of peak instantaneous pressure 
gradients measured across prosthetic valves of the same 
size and little difference between valves of different 
sizes (Figure 6.15). The three patients identified as 
having impaired ventricular function with fractional 
shortening of less than 25% had values that were not 
dissimilar from patients with normal ventricular function 
(Figure 6.15).
There was also a wide variation in mean pressure 
gradient across prostheses of different sizes (Fig 6.16). 
Comparison of Pressure Gradients across Prosthetic— Valves
of Different Type
The distribution of sizes of prostheses was similar 
between patients with Bjork-Shiley and those with porcine 
prostheses and there was considerable overlap in measured 
pressure gradients across prostheses of different sizes. 
Therefore all patients with one type of prosthesis were 
considered together. The patients with impaired
ventricular function were also included, as results based 
on their inclusion or exclusion did not differ
significantly.
The mean of mean pressure_3£adj^ across the Bjork-
85
Comparison of mean pressure gradient (mean press) and peak 
instantaneous pressure gradient (peak press) for patients 
with porcine aortic valve replacements.
FIGURE 6.14
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FIGURE 6.15
Peak instantaneous pressure gradients across Bjork-Shiley 
and porcine aortic valve prostheses of different sizes. 
Values for patients with impaired ventricular function 
(fractional shortening < 25%) are indicated by arrows.
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Mean pressure gradients across Bjork-Shiley and porcine 
aortic valve prostheses of different sizes. Values for 
patients with impaired ventricular function (fractional 
shortening < 25%) are indicated by arrows.
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Shiley aortic prostheses was 11 . 3  ± 4 . 8  rnmHg, and that
across the porcine prostheses was 10.7 ± 5.5 imnHg (Figure
7) . The mean of peak— instantaneous pressure gradient
across the Bjork-Shiley aortic prostheses was 20.9 ± 9.2
mmHg and that across the porcine prostheses was 19.9 ± 10.5
mmHg (Figure 6.18). There was no significant difference 
between these values.
DISCUSSION
We have shown by means of Doppler echocardiography a
small but significant difference in the haemodynamic
performance at rest of the Bjork-Shiley 60° tilting disc
mechanical prosthesis compared with the Hancock and
Carpentier-Edwards porcine prostheses in the mitral
position eight to twelve years after implantation.
Pressure half-time was shorter in the patients with the
Bjork-Shiley prosthesis compared with those with the
Hancock and Carpentier-Edwards porcine prostheses. Mean 
pressure
gradient was lower in patients with the Bjork-Shiley 
prosthesis than those with porcine prostheses in the mitral 
position, but the difference was not significant.
Mean pressure gradient has consistently been shown to 
be the Doppler derived measurement which most clearly 
correlates with data obtained by cardiac catheterisation. 
Pressure half-time is a reliable index of the degree of 
native mitral stenosis and has also been shown to correlate 
with the degree of prosthetic obstruction. Peak
instantaneous pressure gradient is not used in the
assessment of mitral valve obstruction by cardiac 
catheterisation. We have shown little correlation between
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FIGURE 6.17
Mean values (±SD) of mean pressure gradient across Bjork- 
Shiley and porcine aortic valve prostheses.
















Mean values (±SD) of peak instantaneous pressure gradient 
across Bjork-Shiley and porcine aortic valve prostheses.
FIGURE 6.18
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m i t r a l  v a l v e  o b s t r u c t i o n .
en patients with mitral prostheses were exercised 
there was a similar rise in mean pressure gradient across 
both the Bjork-Shiley and porcine prostheses. There was no 
significant change with exercise in the mean of pressure 
time in patients with the Bjork-Shiley prosthesis, but 
there was a significant fall in pressure half-time in those 
with porcine prostheses. This change in the Doppler 
characteristics of the porcine prostheses with exercise 
suggests that there could be an increase in the effective 
orifice area of these prostheses with the increased flow 
across them that occurs with exercise. The difference in 
pressure half-times noted at rest with both types of 
prostheses probably does not therefore reflect an important 
difference in haemodynamic performance between these types 
of prostheses when used in the mitral position.
We have observed no significant difference in 
haemodynamic performance between the Bjork-Shiley and 
Hancock or Carpentier-Edwards porcine prostheses 8-12 years 
after implantation when used in the aortic position. Mean 
pressure gradient was similar for both groups of patients 
with Bjork-Shiley and porcine aortic valve prostheses. 
Peak instantaneous pressure gradient was also similar for 
both groups. Peak instantaneous pressure correlated well 
with mean pressure for patients with both Bjork-Shiley and 
porcine aortic valve prostheses.
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The most obvious limitations of this study are those 
of selection bias and sample size. Almost twice as many 
patients with Bjork-Shiley mitral valve prostheses were 
studied compared with patients with porcine prostheses. 
Most patients agreed to come to the hospital for a special 
visit but it is possible that some patients who did not 
wish to travel for an extra visit were deterred from doing 
so by limiting symptoms; this could have been related to 
dysfunction of their valve prosthesis. Most patients were 
contacted by letter or telephone following their reply to 
the guestionnaire described in Chapter 4 and only a few 
refused to come because of limitation of activities, the 
principle reason given for absence was the need to travel 
some distance for an extra visit.
Reoperation for prosthetic failure has been required 
by a larger number of patients with porcine mitral valve 
prostheses and this has reduced the number of potential 
patients with porcine mitral prostheses available for 
study. Only 33 patients in the Edinburgh valve trial who 
underwent single mitral valve replacement with a porcine 
prosthesis remain alive with the original prosthesis 
intact, and sixteen of these were included in the study 
using Doppler echocardiography. In total of the 241 late 
survivors of the original valve study 95 underwent a
Doppler examination.
In the VA study haemodynamic assessment was carried 
out 6 months after valve replacement in 248 of 575 patients 
enrolled in the study with examinations being carnea out
Limitations of the Study
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in 13 different medical centres and supported by the 
considerable resources of the Veterans Administration. Our 
research would have been stronger if it had been possible 
to include all 241 survivors (or the majority thereof) in 
the examination by Doppler echocardiography, but limited 
availability of Doppler eguipment and the distribution of 
the patients over a large geographical area restricted the 
number of patients that could/would attend for the 
examination. The conclusions to be drawn from this study 
are also limited because Doppler examinations were not 
carried out immediately after the original surgery as well 
as at 8-12 years after implantation. If this information 
had been available any observed changes in Doppler indices 
would have been informative and might have been attributed 
to changes over time of the performance of the prostheses.
Because of these limitations the conclusion to be 
drawn from the observed differences at rest in pressure 
half-time in the Bjork-Shiley and porcine mitral prostheses 
must be limited; the differences could be due to a 
deterioration in porcine valve function over time. The 
greater fall in pressure half-time that occurred with 
exercise in patients with porcine mitral prostheses 
compared with Bjork-Shiley mitral prostheses suggests 
however that there is no significant difference in 
haemodynamic performance between these two types of 
prosthesis. The difference in pressure half-time between 
these types of prosthesis at rest may be due to an initial 
difference in the Doppler echocardiographic
characteristics. For this reason it was interesting to
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make a comparison of the results of Doppler




Almost all previous assessments of prosthetic valves 
by Doppler echocardiography have used peak instantaneous 
pressure (or maximum velocity) and pressure half-time for 
mitral prostheses. Wilkins et al (1986) calculated mean 
pressure across tricuspid and mitral prostheses suspected 
of being obstructive. This was in a small series of 12 
patients with mitral and tricuspid prostheses in whom they 
performed simultaneous catheter and Doppler measurements of 
mean gradient finding the two methods produced results in 
close agreement.
Peak velocity or peak instantaneous pressure across 
the mitral valve would be expected to vary with different 
loading conditions affecting left atrial pressure, and 
indeed we have shown a poor correlation between peak 
instantaneous pressure and mean gradient. The values of 
peak velocity recorded across mitral prostheses in our 
study showed a wide variation in patients with both porcine 
and Bjork-Shiley prostheses. The values obtained did not 
differ from those reported in other series (Tables 6.4 and
6.5). Similarly there was a wide variation in pressure 
half-time in patients in our study and in those reported by 
others. Pressure half-time was similar for patients m  our 
study and in other studies. Greater pressure half-times




prostheses than for Bjork-Shiley prostheses (Tables 6.4 and
6.5). Most patients studied in other series had prostheses 
which had been implanted only a few years previously and 
none more than eight years previously. Gibbs et al (1986) 
noted a non-significant trend towards an increase in 
pressure half-time increasing with time since implantation 
of the Carpentier-Edwards mitral prosthesis. Ryan 
(personal communication) noted a mean pressure half-time of 
124 msec for valves implanted less than 4 years previously, 
and 148 msec for those implanted more than 4 years 
previously. The similarity of the results of our study 
compared with the results of other series do not however 
suggest that there is a significant deterioration in 
haemodynamic performance of porcine prostheses over this 
period of time. The consistently greater pressure half- 
time, albeit small, observed with porcine mitral prostheses 
suggests rather that this is an inherent Doppler 
echocardiographic characteristic of these prostheses when 
used in the mitral position. The fall in pressure half-time 
with exercise that occurred in patients with porcine mitral 
prostheses also suggests that the differences observed at 
rest do not represent an important haemodynamic advantage 
for the Bjork-Shiley prosthesis.
Aortic prostheses
We have shown that haemodynamic performance of the 
Bjork-Shiley, Hancock and Carpentier-Edwards prostheses is 
similar in the aortic position 8 - 1 2  years after 
implantation.
The results of measurements of peak instantaneous
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pressure gradient in our study are similar to those 
reported by others in patients with prostheses implanted 
for lesser periods of time (Tables 6.6, 6.7). Peak
instantaneous pressure gradient was indeed lower than in 
some other studies and there is therefore no suggestion of 
deterioration of haemodynamic performance with increasing 
age of the prosthesis. Mean gradient has not been reported 
in other studies and comparison is not possible.
Conclusions
We can only conclude that within the restrictions of 
our study, measurements using Doppler non-invasive 
techniques indicate no quantifiable deterioration or 
difference in the haemodynamic performance of Bjork-Shiley 
or porcine prostheses used in the mitral or aortic 
positions for periods extending 8 to 12 years after 
implantation. There are severe limitations in data 
available and we would suggest that Doppler measurements be 
included in the examination of selected patients receiving 
replacement valves soon after their operation; this early 
data would provide a useful baseline for comparison with 
subsequent non-invasive measurements taken as the valves 
age in use.
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From 1975 to 1979 in Edinburgh Royal Infirmary 540 
patients were entered into a randomised trial and received 
either a mechanical (Bjork-Shiley) or porcine heterograft 
(Hancock or Carpentier-Edwards) prosthesis. The principle 
advantage of the porcine heterograft prosthesis is that 
patients do not necessarily reguire to take anticoagulant 
treatment. After a mean period of 5 years of follow-up no 
significant advantage to any of these three prostheses had 
been observed.
In 1977 the Veterans Administrations (VA) in the 
United States started a similar randomised trial comparing 
the Bjork-Shiley with the Hancock prosthesis. After a mean 
period of 5 years of follow-up there was also no 
significant difference in patient survival but there was a 
significantly increased occurrence of clinical 
complications related to the valve prosthesis in those 
receiving a Bjork-Shiley prosthesis. These complications 
were related to a greater incidence of bleeding in patients 
with this prosthesis necessitating long-term treatment 
with anticoagulants; this finding was at variance with the 
results of the Edinburgh study in which bleeding occurred 
much less frequently. The difference in results was 
attributed to differences in the methods of control of 
anticoagulant treatment in Edinburgh, and in the United 
States, and also to differences in the populations studied.
The work has been extended in Edinburgh and after a 
mean follow-up period of 10.5 years we have observed no
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difference m  survival between those receiving a mechanical 
or a porcine prosthesis. Reoperation for valve failure, 
however, was necessary in significantly more patients with 
a porcine prosthesis than in those receiving a Bjork-Shiley 
prosthesis. Seventeen patients with the Bjork-Shiley, and 
53 with a porcine prosthesis (20 with Hancock, and 33 with 
Carpentier-Edwards) have reguired reoperation to replace 
the randomised prosthetic valve. This difference was 
almost exclusively due to cusp failure of porcine 
prostheses occurring more than 5 years after implantation.
Degeneration of porcine prostheses might be gradual, 
and failure of a mechanical prosthesis might be abrupt and 
catastrophic, and we thought it possible that the number of 
patients undergoing reoperation for failure of a porcine 
prosthesis might possibly have been offset by a similar 
number of patients with Bjork-Shiley prostheses dying 
suddenly due to prosthetic failure. We therefore examined 
actuarial survival with reoperation or cardiac death as an 
end point. Actuarial survival-free from reoperation or 
cardiac death was significantly higher in those receiving a 
Bjork-Shiley prosthesis than in those receiving a porcine 
prosthesis when all patients and those receiving a mitral 
valve replacement were considered, but not when those 
receiving an aortic valve replacement were considered.
Bleeding occurred on 34 occasions in 28 patients with 
the Bjork-Shiley, and on 18 occasions in 15 patients with 
porcine prostheses. Death and valve related events 
(reoperation, bleeding and complications of
anticoagulation, systemic embolism and bacterial
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endocarditis) were considered as end-points for actuarial 
analysis. There was a non significant trend towards
improved actuarial "event-free" survival for those patients 
receiving the Bjork-Shiley prosthesis when all patients, 
and those receiving a mitral valve replacement were 
considered, but not when those receiving aortic valve 
replacement were considered. The differences demonstrated 
between prostheses in the Edinburgh trial have only become 
apparent after ten years, and this emphasises the 
importance of such a period of observation in the 
evaluation of heart valve prostheses.
Doppler ultrasound techniques have been used to 
compare the haemodynamic performance of the Bjork-Shiley 
and porcine prostheses, an average of 10 years after 
implantation, in 102 patients enrolled in the Edinburgh 
Trial. No significant difference in peak instantaneous 
pressure gradient, or mean pressure gradient across the 
prosthesis was observed in patients who had undergone 
either aortic valve replacement, or mitral valve 
replacement.
Pressure half-time is a Doppler-derived index of 
obstruction used to evaluate stenotic mitral valves. We 
found a significantly lower pressure half-time in patients 
with the Bjork-Shiley mitral valve prosthesis compared with 
patients with porcine mitral valve prostheses. Some of 
these patients underwent exercise testing, and pressure 
half-time was observed to fall with exercise in those with 
porcine prostheses, but remained unchanged in those with 
Bjork-Shiley prostheses. This suggests that the
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differences in pressure half-time observed at rest do not 
represent an important haemodynamic advantage for the 
Bjork-Shiley prosthesis.
We compared the results obtained in this study with 
those reported in other series of Doppler echocardiographic 
evaluations of Bjork-Shiley and porcine prostheses. We 
conclude from our measurements and from this comparison 
that there is no guantifiable deterioration or difference 
in the haemodynamic performance of Bjork-Shiley or porcine 
prostheses used in the mitral or aortic positions for 
periods extending 8 - 1 2  years after implantation. There 
are limitations in the data available and we would suggest 
that in future Doppler measurements might be included in 
the examination of selected patients receiving replacement 
valves soon after their operation and that this early data 
would provide useful baseline information for comparison 
with subsequent non-invasive measurements taken as the 
valves age in use.
In the light of these results what recommendation for 
the selection of type of prosthesis for patients undergoing 
valve replacement can be made? Our results suggest that 
patients who because of atrial fibrillation, or for other 
reasons would normally continue anticoagulants after valve 
replacement should receive a mechanical prosthesis. In our 
practice this would include the majority of patients 
undergoing replacement of the mitral valve. Indeed, with 
the increased risk of reoperation more than 5 years after 
implantation of the prosthesis it would appear that 
patients undergoing mitral valve replacement should
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receive a mechanical prosthesis unless there is a clear 
contra-indication to anticoagulants. There is no apparent 
clear advantage for the use of a mechanical prosthesis in 
those undergoing aortic valve replacement, but younger 
patients could benefit from a mechanical prosthesis of 
proven durability.
It is important that anticoagulant control should not 
lead to an increased risk of bleeding, and warfarin control 
at a prothrombin ratio of 2.0 - 4.0 in the United Kingdom, 
which is equivalent to a ratio of 1.3 - 2.0 in the U.S.A., 
would appear to give a satisfactory reduction in the risk 
of embolism, without excessive risk of bleeding.
Porcine bioprosthetic valves will continue to be 
useful for patients in whom anticoagulants must be avoided, 
but this selection should be made in the knowledge that 
with these prostheses there is a greater probability that a 
second operation could be required due to valve 
deterioration at a later date.
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